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1 Introduction 
 
 
1.1 Coronaviruses 
 
1.1.1 Taxonomy 
Coronaviruses (CoVs) belong to the family Coronaviridae that include the 
subfamilies Coronavirinae and Torovirinae. This virus family was established in 1975 
by the International Committee on Taxonomy of Viruses (ICTV) (Tyrrell et al. 1975). 
The family Coronaviridae together with the families Arteriviridae, Mesoniviridae and 
Roniviridae form the order Nidovirales (Adams et al. 2013; de Groot et al. 2012b). 
Generation of a 3’-coterminal set of subgenomic mRNAs (sg mRNAs) during 
transcription is a hallmark of all members of the order Nidovirales. These sg mRNAs 
are called ‘nested set’ (lat. nidus = nest) (de Groot et al. 2012b). Although the 
members of the order Nidovirales differ in the morphology of virions, size of the 
genome and the number of encoded accessory proteins (Siddell et al. 2005), they 
share similarities based on their replicase polyproteins that contain a number of 
characteristic domains arranged in a conserved order (Brierley et al. 1987; Brierley 
1995; Cowley et al. 2000; Snijder et al. 2016). 
 
Genus Species 
Alphacoronavirus Alphacoronavirus-1 
      Feline coronavirus (FCoV) 
      Canine coronavirus (CCoV) 
      Transmissible gastroenteritis virus (TGEV) 
      Porcine respiratory coronavirus (PRCoV) 
 Porcine epidemic diarrhea virus (PEDV) 
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 Bat coronavirus CDPHE15 (BatCoV CDPHE15) 
 Bat coronavirus HKU10 (BatCoV HKU10) 
 Miniopterus bat coronavirus 1 (Mi-BatCoV 1) 
 
Miniopterus bat coronavirus HKU8 (Mi-BatCoV HKU8) 
Mink coronavirus 1 (MCV) 
 Rhinolophus bat coronavirus HKU2 (Rh-BatCoV HKU2) 
 Scotophilus bat coronavirus 512 (Sc-BatCoV 512) 
 Human coronavirus 229E (HCoV 229E) 
 Human coronavirus NL63 (HCoV NL63) 
Betacoronavirus Betacoronavirus-1 
      Bovine coronavirus (BCoV) 
      Porcine hemagglutinating encephalomyelitis virus (PHEV) 
      Equine coronavirus (ECoV) 
      Human coronavirus OC43 (HCoV OC43) 
 
Hedgehog coronavirus 1 (EriCoV) 
Middle East respiratory syndrome coronavirus (MERS-CoV) 
 Murine coronavirus  
      Mouse hepatitis virus (MHV) 
      Rat coronavirus (RCoV) 
 
Severe acute respiratory syndrome-related coronavirus 
(SARS-CoV) 
 Human coronavirus HKU1 (HCoV HKU1) 
 Pipistrellus bat coronavirus HKU5 (Pi-BatCoV HKU5) 
 Rousettus bat coronavirus HKU9 (Ro-BatCoV HKU9) 
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 Tylonycteris bat coronavirus HKU4 (Ty-BatCoV HKU4) 
Gammacoronavirus Avian coronavirus 
      Infectious bronchitis virus (IBV) 
      Turkey coronavirus (TCoV) 
      Pheasant coronavirus (PhCoV) 
 Bottlenose dolphin coronavirus HKU22 (BdCoV HKU22) 
 Beluga whale coronavirus SW1 (BWCoV SW1) 
Deltacoronavirus  Bulbul coronavirus HKU11 (BuCoV HKU11) 
 Common moorhen coronavirus HKU21 (CMCoV HKU21) 
 
Munia coronavirus HKU13 (MunCoV HKU13) 
Porcine coronavirus HKU15 (PorCoV HKU15) 
 Night heron coronavirus HKU19 (NHCoV HKU19) 
 Thrush coronavirus HKU12 (ThCoV HKU12) 
 White-eye coronavirus HKU16 (WECoV HKU16) 
 Wigeon coronavirus HKU20 (WiCoV HKU20) 
Table 1. Coronavirinae subfamily. Genera, species and abbreviations of the virus names are listed. 
 
Based on phylogenetic analysis, the subfamily Coronavirinae is divided into genera 
Alpha-, Beta-, Gamma- and Deltacoronavirus (Table 1). Feline coronaviruses, which 
represent the focus of this work, together with closely related canine coronavirus 
(CCoV), porcine transmissible gastroenteritis virus (TGEV) and porcine respiratory 
coronavirus (PRCoV) belong to the species Alphacoronavirus-1 within the genus 
Alphacoronavirus. Other members of this genus are more distantly related viruses 
like porcine epidemic diarrhea virus (PEDV), human coronaviruses 229E (HCoV-
229E) and NL63 (HCoV-NL63). Coronaviruses detected in minks and some bat 
species also belong to this genus (de Groot et al. 2012a). The genus 
Betacoronavirus contains important animal viruses like bovine CoV (BCoV), equine 
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CoV (ECoV) and porcine hemagglutinating encephalomyelitis virus (PHEV). Human 
betacoronaviruses are the severe acute respiratory syndrome-coronavirus (SARS-
CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and human 
coronavirus OC43 (HCoV OC43). Recently, a novel betacoronavirus related to 
MERS-CoV was isolated from European hedgehogs (Corman et al. 2014). 
Coronaviruses pathogenic for mice, rats and bats are also part of this genus. The 
genus Gammacoronavirus contains avian viruses like infectious bronchitis virus 
(IBV), turkey coronavirus (TCoV) and pheasant coronavirus (PhCoV) (Cavanagh et 
al. 2002). Recently, beluga whale coronavirus SW1 (BWCoV SW1) and bottlenose 
dolphin coronavirus HKU22 (BdCoV HKU22) were added to this genus 
(Mihindukulasuriya et al. 2008; Woo et al. 2014). In 2009, three avian coronaviruses, 
bulbul coronavirus HKU11 (BuCoV HKU11), munia coronavirus HKU13 (MunCoV 
HKU13) and thrush coronavirus HKU12 (ThCoV HKU12) were identified and 
clustered under the new coronavirus genus – Deltacoronavirus (Woo et al. 2009). 
Besides these avian coronaviruses, porcine coronavirus HKU15 (PorCoV HKU15) 
belongs to this genus as well.  
 
1.1.2 Morphology 
Coronaviruses are enveloped, pleomorphic, mostly spherical with a diameter ranging 
between 120 and 160 nm (Fig. 1A). Virions are surrounded by characteristic surface 
projections (ca. 20 nm) consisting of trimers of the spike glycoprotein (S) (Cavanagh 
1983; Delmas & Laude 1990). The name ‘coronavirus’ is derived from the petal-
shaped surface projections resembling the corona of the Sun observed in electron 
micrographs (Davies & Macnaughton 1979).  
Beside the spike glycoprotein (180-220 kDa), the membrane (M) protein (25-30 kDa) 
and the envelope (E) protein (10-12 kDa) are also integrated into the envelope of the 
virion (Fig. 1B). The spike protein is a glycosylated transmembrane protein that is 
important for receptor binding and fusion of the virions with the cellular membrane 
(Kubo et al. 1994; McBride & Machamer 2010; Yoo et al. 1991). Furthermore, this 
protein is responsible for induction of neutralizing antibodies (Compton et al. 1993). 
The membrane protein (M) binds the nucleocapsid (N) through its C-terminal domain 
and is crucial for particle assembly (Escors et al. 2001; Narayanan et al. 2000; 
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Rottier 1995). The envelope protein (E) was shown to be involved in virion assembly 
and morphogenesis. Furthermore, it was identified as a virulence factor for SARS-
CoV (de Groot et al. 2012a; DeDiego et al. 2011). Certain members of the genus 
Betacoronavirus contain additional surface projections (5-7 nm in length) formed by 
the homodimeric hemagglutinin-esterase (HE) glycoprotein (60-65 kDa). This protein 
mediates reversible attachment of virions to O-acetylated sialic acids (King et al. 
1985; Langereis et al. 2010; Vlasak et al. 1988). The envelope of the virion 
surrounds the nucleocapsid, which consists of the RNA genome and the 
nucleocapsid (N) protein (43-63 kDa) (Fig. 1B) (Baric et al. 1988). In addition to 
genome encapsidation, the N protein plays an important role in transcription and 
translation of viral mRNAs. It also acts as type I interferon antagonist (Almazan et al. 
2004; Baric et al. 1988; Ding et al. 2014; Laude & Masters 1995; Lu et al. 2011; 
Rose & Weiss 2009; Ye et al. 2007). 
Figure 1. Coronavirus morphology. (A) Electron micrograph of negatively stained porcine epidemic 
diarrhea virus (PEDV) particle (Hanke et al. 2015). (B) Schematic representation of an 
Alphacoronavirus particle. Structural proteins and RNA are shown. 
1.1.3 Genome Organization 
Coronaviruses possess a linear, single-stranded, non-segmented RNA genome of 
positive polarity with a size of 27-31.5 kilobases (kb); these are the largest viral RNA 
genomes in nature (Gorbalenya et al. 2006). Similar to eukaryotic mRNAs, the CoV 
 
- 6 - 
 
genome is capped at the 5’ end (Lai & Stohlman 1981) and polyadenylated at the 3’ 
end (Lai & Stohlman 1978; Lomniczi 1977; Masters 2006; Schochetman et al. 1977; 
Wege et al. 1978). These features allow translation of the viral RNA by the cellular 
machinery directly after infection. As was shown before, coronaviral RNA alone is 
infectious and can initiate the CoV replication cycle (Almazan et al. 2000; Casais et 
al. 2001; Scobey et al. 2013; Tekes et al. 2008; Tekes et al. 2012; Thiel et al. 2001a; 
Yount et al. 2000; Yount et al. 2002; Yount et al. 2003). 
The 5’ end of the CoV genome comprises an untranslated region (UTR) of about 
200-500 nt. The first 65-98 nucleotides comprise the so called Leader-sequence, 
which is also present at the 5’ end of all viral subgenomic RNAs (Lai & Holmes 2001; 
Lai & Cavanagh 1997). The 3’ end of the genome also contains an UTR with a size 
of about 200-400 nt. Both UTRs contain cis-active elements, which are essential for 
viral replication and transcription of the coronavirus genome (Chang et al. 1994; 
Madhugiri et al. 2014; Madhugiri et al. 2016; Masters 2007; Raman et al. 2003; Sola 
et al. 2011; Zust et al. 2008). 
The coronavirus genome contains 6 to 14 open reading frames (ORFs). The order of 
the ORFs from 5’ to 3’ end is conserved for all CoVs: replicase gene-S-E-M-N (Fig. 
2) (de Haan et al. 2002). The replicase gene occupies two thirds of the genome (ca. 
20 kb) and contains ORF 1a and ORF 1b. ORF 1a encodes a polyprotein (pp) pp1a 
with a molecular mass of 450-500 kDa (Siddell et al. 2005). ORF 1b is translated 
through a -1 ribosomal frameshifting (RFS) into a 750-800 kDa pp1ab (Brierley et al. 
1989; Siddell et al. 2005). The so called ‘slippery’ sequence (UUUAAAC) and an 
RNA structure (pseudoknot) positioned downstream of this sequence are essential 
for the ribosomal frameshifting. In case of a -1 frameshift, the ribosome is stalled on 
the ‘slippery’ sequence by the pseudoknot structure and it backtracks one nucleotide 
(Brierley et al. 1989; Brierley 1995). Both pp1a and pp1ab are cleaved by virus-
encoded proteinases into 15-16 nonstructural proteins (nsps) that form the 
replication and transcription complexes (Snijder et al. 2016; Ziebuhr et al. 2000). 
The 3’-proximal one-third of the genome codes for structural proteins S, E, M and N 
and accessory proteins. The number and position of the accessory genes in the CoV 
genome varies between species (Fig. 2) (de Groot et al. 2012a). 
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Figure 2. Schematic representation of the FCoV genome. ORF 1a and 1b are marked in blue, 
genes encoding structural proteins in red and accessory genes in green. 5’ Cap structure is shown as 
a black dot; L, Leader-sequence (grey box) is followed by transcription regulatory sequence (TRS, 
black box); ribosomal frameshift is depicted with an arrow; (A)n, poly-(A) tail; kb, kilobase. 
1.1.4 Replication of Coronaviruses 
Coronaviruses bind through the S protein to the appropriate receptor of the host cell. 
Different CoVs use distinct receptors for this purpose. Serotype II FCoV, serotype II 
CCoV, TGEV, PRCoV, PEDV and HCoV-229E bind to aminopeptidase N (APN or 
CD13) (Delmas et al. 1992; Hohdatsu et al. 1998; Kolb et al. 1998; Li et al. 2007; 
Tresnan et al. 1996; Yeager et al. 1992). For serotype I and II FCoVs, C-type lectin 
dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (fDC-
SIGN) has been identified as a co-receptor (Regan & Whittaker 2008; Regan et al. 
2010; Van Hamme et al. 2011). Further cellular receptors used by coronaviruses 
include angiotensin-converting enzyme 2 (ACE2) for human pathogens HCoV-NL63 
and SARS-CoV (Hofmann et al. 2005; Li et al. 2003), murine carcinoembryonic 
antigen-related cell adhesion molecule 1 (CEACAM1 or CD66a) for MHV (Dveksler 
et al. 1991; Dveksler et al. 1993; Taguchi & Hirai-Yuki 2012). Some 
betacoronaviruses like BCoV and HCoV-OC43 bind to sialic acids (Krempl et al. 
1995; Schwegmann-Wessels & Herrler 2006). Binding of the S protein to cellular
receptors triggers a conformation change of the spike protein and fusion of the viral 
and the cellular membranes resulting in internalization of the viral genome as shown 
e.g. for MHV (Nash & Buchmeier 1997). Other CoVs like FCoV, TGEV, HCoV-229E 
and IBV infect cells through receptor-mediated endocytosis. Internalized virions fuse 
with the endosomal membrane followed by release of the nucleocapsid into the 
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cytoplasm of the host cell (Blau & Holmes 2001; Chu et al. 2006; Hansen et al. 1998; 
Van Hamme et al. 2007). 
The positive strand RNA genome of CoVs serves as mRNA in infected cells and is 
directly translated in the cytoplasm. Translation gives rise to pp1a and, through a -1
ribosomal frameshifting, pp1ab. Both of these polyproteins are co- and post-
translationally processed into usually 16 nonstructural proteins (nsps) by a set of 
virus-encoded proteinases (Fig. 3) (Ziebuhr et al. 2000). ORF 1a encodes 3 
proteinases: two papain-like proteinases (PL1pro and PL2pro) and the main proteinase 
(3C-like protease, Mpro). PL1pro and PL2pro are responsible for processing the N-
terminal end of the pp1a/pp1ab. For these proteinases, three cleavage sites were 
identified (Ziebuhr et al. 2001). The C-terminal end of pp1a/1ab is processed by Mpro
at 11 identified cleavage sites (Snijder et al. 2016; Ziebuhr et al. 1995; Ziebuhr & 
Siddell 1999; Ziebuhr et al. 2000). Together with cellular proteins, the nonstructural 
proteins form the replication/transcription complex (RTC), which is associated with 
double-membrane vesicles (DMVs). The RTC is responsible for replication and 
transcription of viral genome (Gosert et al. 2002; Harcourt et al. 2004; Prentice et al. 
2004; Sawicki et al. 2005; Snijder et al. 2006; Thiel et al. 2001b). 
Figure 3. Schematic representation of the proteolytic processing of pp1a and pp1ab. Cleavage 
sites for the papain-like proteinases (PL1pro and PL2pro) are shown with black arrows and cleavage 
sites for the main proteinase (Mpro) with white arrows. Nonstructural proteins (nsp1-16) are indicated. 
Modified after Snijder et al. (2016). 
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Replication of the coronavirus genome starts with negative strand RNA synthesis. 
The negative strand RNA serves as a template for generation of positive strand 
genomic RNAs. These RNAs are either translated into pp1a/pp1ab or packed into 
nucleocapsids (Weiss & Navas-Martin 2005).
Structural and accessory proteins are expressed form a nested-set of 3’ co-terminal 
subgenomic mRNAs (sg mRNAs) (Siddell et al. 2005). All of these sg mRNAs 
possess an identical 3’ end, which corresponds to the 3’ end of the genomic RNA. At 
the 5’ end sg mRNAs possess the Leader-sequence followed by a various number of 
ORFs (Fig. 4). Usually, only the first ORF of a sg mRNA is translated. Accordingly, 
coronavirus sg mRNAs are structurally polycistronic, but functionally monocistronic 
(Lai & Cavanagh 1997).
Figure 4. Expression strategy of coronaviruses. ORFs are shown with boxes. Black line 
downstream of the first ORF represents the non-translated region of the mRNA. 5’ Cap structure is 
demonstrated with a black dot; L, Leader-sequence (grey box) is followed by transcription regulatory 
sequence (TRS, black box); (A)n, poly-(A) tail. Modified after Tekes (2008). 
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Subgenomic mRNAs are generated through discontinuous transcription during 
negative strand synthesis (Pasternak et al. 2001; Sawicki & Sawicki 1995). The so 
called transcription regulatory sequence (TRS) plays an essential role in this 
process. TRS is located in the coronavirus genome at the 3’ end of the Leader-
sequence (Leader-TRS) and upstream of each ORF (Body-TRS) (Lai & Holmes 
2001). The synthesis of negative strand sg mRNAs starts at the 3’ end of the 
genomic RNA. After the synthesis of the negative strand Body-TRS, the newly 
synthesized subgenomic RNA (- sgRNA) dissociates from the genomic RNA and 
translocates to the 5’ end of the genome, where it binds through base pairing to the 
Leader-TRS. Then, the negative strand synthesis is continued and completed by 
adding the complement of the Leader-sequence. The synthetized - sgRNA serves as
template for the generation of plus strand sg mRNAs, which are used for the 
translation of structural and accessory genes (Pasternak et al. 2001; Sawicki & 
Sawicki 1995). Schematic model of subgenomic mRNA synthesis is demonstrated in 
Figure 5. 
Figure 5. Schematic representation of subgenomic RNA synthesis. (A) Synthesis of negative 
strand sgRNA starts at the 3’ end of the genome and pauses at Body-TRS. (B) Newly synthesized  
- sgRNA is translocated to the 5’ end of the genome and binds through base pairing to the Leader-
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TRS. Negative strand synthesis is continued until the complement of the Leader-sequence is added. 
(C) - sgRNA serves as a template for sg mRNAs synthesis. Modified after Tekes (2008). 
Viral structural proteins synthesized from sg mRNAs are assembled in the 
endoplasmic reticulum-Golgi intermediate compartment (ERGIC) into new virions 
(Klumperman et al. 1994; Tooze et al. 1984) that are transported in vesicles to the 
plasma membrane and exocytozed (Lai & Holmes 2001; Siddell et al. 1983). 
 
1.2 Feline Coronaviruses 
Feline coronaviruses (FCoVs) are spread worldwide; they infect domestic as well as 
wild members of the family Felidae (Heeney et al. 1990; Hofmann-Lehmann et al. 
1996; Munson et al. 2004; O'Brien et al. 1985; Paul-Murphy et al. 1994; Pedersen 
2009). In single-cat households, seropositivity of FCoVs reaches 10-50%, while in 
multi-cat households and animal shelters 80-90% of the cats are seropositive 
(Herrewegh et al. 1995; Pedersen et al. 1981; Pedersen & Black 1983). Most 
animals get infected in their first few weeks after birth, when the protection by 
maternal antibodies declines (Addie et al. 2009; Pedersen et al. 1981). Infected 
animals usually develop a persistent infection that can last from few months to few 
years (Addie & Jarrett 2001; Addie et al. 2003; Foley et al. 1997; Gunn-Moore et al. 
1998; Herrewegh et al. 1995; Herrewegh et al. 1997). 
Feline coronaviruses are divided into two serotypes (I and II) (Heeney et al. 1990; 
Hohdatsu et al. 1991a; Kennedy et al. 2003). Serotype I FCoVs are responsible for 
up to 95% of the natural infections (Addie et al. 2003; Hohdatsu et al. 1992; Kennedy 
et al. 2002; Kummrow et al. 2005). Serotype II FCoVs are less common in Europe or 
USA, but are more often found in Asia, where they can cause up to 25% of infections 
(Amer et al. 2012; An et al. 2011; Sharif et al. 2010). Serotype II FCoVs evolved 
through a double homologous recombination between serotype I FCoVs and canine 
coronavirus serotype II (CCoV). As a result of the recombination, serotype II FCoVs 
contain the S gene and surrounding regions of the CCoV in the backbone of a 
serotype I FCoV (Decaro & Buonavoglia 2008; Haijema et al. 2007; Herrewegh et al. 
1998; Lin et al. 2013; Lorusso et al. 2008; Motokawa et al. 1996; Terada et al. 2014; 
Vennema 1999). According to the different origin of S genes in serotype I and II 
FCoVs, the in vitro growth characteristics of the two serotypes differ. While serotype 
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II FCoVs grow in cell culture, serotype I viruses do not grow in vitro (de Haan et al. 
2005; Dye &Siddell 2005; Haijema et al. 2003; Haijema et al. 2004; Rottier et al. 
2005; Tekes et al. 2012). 
Based on pathogenicity, FCoVs are classified into two biotypes (Vennema 1999). 
Feline enteric coronavirus (FECV) leads usually to a persistent asymptomatic 
infection, while feline infectious peritonitis virus (FIPV) causes a lethal, 
immunopathological disease called feline infectious peritonitis (FIP) (Pedersen 2009; 
Poland et al. 1996). The horizontal transfer of FECVs occurs through fecal-oral route 
(Garner et al. 2008; Kipar et al. 2006; Pedersen 2009; Pedersen 2014). In contrast, 
FIPVs are usually not transmitted from cat to cat (Pedersen et al. 2012). 
Two theories have been proposed to explain the emergence of FIPVs. The widely 
accepted ‘internal mutation’ theory suggests that FIPV originates from FECV by 
acquiring mutations in persistently infected cats (Chang et al. 2011; Haijema et al. 
2007; Pedersen 2009; Poland et al. 1996; Vennema et al. 1998). This hypothesis 
relies on sequence analyses of FECVs and FIPVs; sequences originating from one 
region are more similar to each other than FECVs or FIPVs sequences from 
geographically distant regions (Chang et al. 2011; Pedersen 2009; Vennema et al. 
1998). The ‘circulating virulent-avirulent FCoV’ hypothesis is based on sequence 
analyses of the M and 7b genes (Brown et al. 2009); they suggested the coexistence 
of virulent and avirulent FCoV strains in cat populations. According to this theory, 
cats are exposed to both virulent and avirulent strains and after infection with a 
virulent strain a susceptible cat develops FIP (Brown et al. 2009). It is important to 
note that this theory has not received any further backing. Subsequent studies have 
actually supported the ‘internal mutation’ theory. So far, mutations responsible for the 
biotype switch have not been identified. However, alterations in the S gene and/or 
accessory genes 3c, 7a and 7b have been suggested to be involved in FIPV 
development (Bank-Wolf et al. 2014; Chang et al. 2010; Chang et al. 2012; 
Dedeurwaerder et al. 2013; Herrewegh et al. 1995; Kennedy et al. 2001; Licitra et al. 
2013; Pedersen et al. 2012; Rottier et al. 2005; Takano et al. 2011; Vennema et al. 
1998). 
One remarkable difference between FCoV biotypes concerns the host cell tropism. 
FECVs primarily infect epithelial cells of the gut (Chang et al. 2010; Herrewegh et al. 
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1997; Kipar et al. 2010; Pedersen et al. 1981; Vogel et al. 2010), while FIPVs 
efficiently replicate in monocytes and macrophages. Upon FIPV infection, monocytes 
get activated and heavily express cytokines, adhesion molecules and enzymes that 
contribute to increased vascular permeability; this leads to extravasation of 
monocytes into tissues and effusion in body cavities (Dewerchin et al. 2005; 
Goitsuka et al. 1990; Kipar et al. 2005; Kipar & Meli 2014; Olyslaegers et al. 2013; 
Regan et al. 2009; Rottier et al. 2005; Stoddart & Scott 1989; Takano et al. 2011; 
Weiss et al. 1988). 
 
1.3 Feline Infectious Peritonitis (FIP) 
Feline infectious peritonitis is a lethal disease caused by FIPV that was first 
described in 1963 (Holzworth 1963). In 1968, electron micrographs of virus particles 
originating from a cat that succumbed to FIP led to the suggestion that feline 
infectious peritonitis is caused by a coronavirus. This hypothesis was confirmed in 
1976 (O'Reilly et al. 1979; Pedersen 1976; Ward 1970; Zook et al. 1968). 
FIP is one of the most important lethal infectious diseases of cats. Although FECV 
infections are very common, FIPV develops only in approximately 5% of the 
persistently infected cats (Chang et al. 2011; Haijema et al. 2007; Pedersen 2009). 
Feline infectious peritonitis affects cats often at an age between 6 months and 2 
years. The incidence of FIP decreases with increasing age (Foley et al. 1997; 
Pedersen 2009). Two clinical forms of FIP can be distinguished. The more common 
effusive form (wet) is characterized by the presence of protein-rich effusions in the 
abdominal and pleural cavities. The non-effusive form (dry) is defined by 
granulomatous lesions in different organs (Drechsler et al. 2011; Hartmann 2005; 
Kipar & Meli 2014; Montali & Strandberg 1972; Pedersen 2009; Pedersen 2014). 
The development of the different forms of FIP is assumed to be dependent on the 
host immune response (Pedersen 2009; Pedersen 2014). 
The incubation time of naturally occurring FIP is difficult to determine. To elucidate it, 
experimental FIPV infections of cats have been performed. The experiments 
revealed an incubation time of 2-14 days for the wet form and several weeks for the 
dry form (Kiss et al. 2004; Pedersen et al. 1981; Pedersen & Black 1983; Pedersen 
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1984; Tekes et al. 2012). After infection, cats developed fever, lack of appetite and 
weight loss.  
Currently, one FIPV vaccine is commercially available, namely Felocell FIP from 
Zoetis. This vaccine contains live, temperature sensitive recombinant serotype II 
FCoV strain DF2 for intranasal application (Christianson et al. 1989; Gerber et al. 
1990a). This virus replicates in the upper respiratory tract and induces 
immunoglobulin A production that confers immunity in the upper respiratory tract 
(Gerber et al. 1990b). However, the efficacy of this vaccine is still debated.  
An efficient therapy against FIP is currently not available. Recently an inhibitor of 
coronavirus 3C-like protease has been shown to reverse the progression of FIP 
under experimental conditions (Kim et al. 2016). Further experiments are required to 
assess this approach in natural FIP cases.  
 
1.4 Accessory Proteins of Coronaviruses 
The 3’-proximal one-third of the coronavirus genome codes for structural and 
accessory proteins (Fig. 2). Accessory proteins of CoVs are dispensable for virus 
growth in vitro, but they are relevant for virus replication and virulence in vivo (Casais 
et al. 2005; de Haan et al. 2002; Haijema et al. 2004; Hodgson et al. 2006; Ontiveros 
et al. 2001; Shen et al. 2003; Yount et al. 2005). The number of accessory genes in 
the coronavirus genomes varies among different species and sublineages from only 
one in Alphacoronavirus HCoV-NL63 (Pyrc et al. 2004) up to 9 in 
Gammacoronavirus BdCoV HKU22 (Woo et al. 2014). Homologs of these genes 
exist only in closely related Coronaviruses (Lai & Cavanagh 1997).  
In alphacoronaviruses, accessory genes are present at two positions: (i) between S 
and E genes, and (ii) downstream of the N gene. FCoVs, as well as closely related 
CCoVs possess three ORFs (3a, 3b, 3c). TGEV contains two (3a and 3b) and other 
viruses, such as PEDV, HCoV-229E and HCoV-NL63 only one ORF (ORF 3). 
Recently, a new ORF named ORF 3 was discovered in this region for CCoV 
(Lorusso et al. 2008). Downstream of the N gene, FCoVs and CCoVs contain two 
ORFs (7a and 7b), while TGEV has only one (ORF 7) (Fig. 6A) (de Groot et al. 
2012a). 
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In betacoronaviruses, accessory genes are located (i) downstream of the replicase 
gene, (ii) between S and E genes, (iii) between M and N genes, and (iv) downstream 
of the N gene. Additionally, an internal ORF within the N gene is present in SARS-
CoV (ORF 9b), MERS-CoV (ORF 8b), HCoV-OC43 (ORF N2), HCoV-HKU1 (ORF 
N2), BCoV (ORF I) and MHV (ORF I) (Liu et al. 2014). The presence of accessory 
gene 2a and the hemagglutinin-esterase gene (HE) downstream of the replicase 
gene is characteristic for lineage A of betacoronaviruses and can be found in BCoV, 
MHV or HCoV OC43. ORF 4 and ORF 5a of this lineage are located between S and 
E genes and an internal ORF within the N gene is present (Fig. 6B). In 
betacoronavirus lineage B, accessory genes are located between M and N gene. In 
this region, SARS-CoV contains ORFs 6, 7a, 7b, 8a and 8b. Additionally, the SARS-
CoV genome contains two ORFs (ORF 3a and 3b) between S and E gene and one 
within the N gene (ORF 9b) (Fig. 6C) (Liu et al. 2014). Betacoronaviruses of lineage 
C, like MERS-CoV, possess ORFs 3, 4a, 4b and 5 between S and E genes. In 
addition, this virus contains one internal ORF (ORF 8b) within the N gene (Fig. 6D). 
Ro-BatCoV HKU9 is a representative of betacoronavirus lineage D. This is the only 
member, in which two ORFs (ORF 7a and 7b) were identified downstream of the N 
gene. Additionally, it contains one ORF (ORF 3) downstream of the S gene (Fig. 6E) 
(Liu et al. 2014).  
The gammacoronavirus IBV contains two ORFs (ORF 3a and 3b) between S and E 
genes and two others (ORF 5a and 5b) downstream of the M gene (Liu & Inglis 
1991; Liu & Inglis 1992a; Liu & Inglis 1992b). Recently, a putative open reading 
frame was identified upstream of the ORF 5a and named ORF 4b (Fig. 6F) (Bentley 
et al. 2013). TCoV genome encompasses additional ORFs downstream of the M 
gene (ORF 4c) and downstream of the N gene (ORF 6b) (Brown et al. 2016). 
Gammacoronaviruses isolated from aquatic mammals, BWCoV SW1 and BdCoV 
HKU22, contain 8 or 9 accessory genes downstream of the M gene, respectively 
(Woo et al. 2014). 
Members of the genus Deltacoronavirus possess one ORF (ORF 6) between M and 
N genes and up to four (ORF 7a-d) downstream of the nucleocapsid gene. Some 
viruses from this genus, like PorCoV HKU15 and WECoV HKU16, contain an 
additional ORF (ORF 7) that is present within the N gene (Fig. 6G) (Fang et al. 2016; 
Woo et al. 2012). 
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Figure 6. Genome organization of representatives of genera Alpha-, Beta- (lineages A-D), 
Gamma- and Deltacoronavirus with focus on accessory genes downstream of ORF 1a and 
ORF 1b. (A) FCoV, Feline coronavirus (NC_002306), (B) MHV, Mouse hepatitis virus (AC_000192),
(C) SARS CoV, Severe acute respiratory syndrome coronavirus (NC_004718), (D) MERS 
CoV,Middle-East respiratory syndrome coronavirus (NC_019843), (E) Bat CoV HKU9, Rousettus bat 
coronavirus HKU9 (NC_009021), (F) IBV, Infectious bronchitis virus (NC_001451), (G) BuCoV 
HKU11, Bulbul coronavirus HKU11 (FJ376619). ORF 1a and 1b are marked in blue, ORFs encoding 
structural proteins in red and accessory genes in green. 5’ Cap structure is shown as a black dot; L, 
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Leader-sequence (grey box) is followed by transcription regulatory sequence (TRS, black box); (A)n, 
poly-(A) tail. Modified after Liu et al.(2014) and Woo et al.(2012). 
 
1.4.1 Accessory Genes and Accessory Proteins of Feline 
Coronaviruses 
The feline coronavirus genome contains five accessory genes: 3a, 3b, 3c between S 
and E genes and 7a, 7b downstream of the nucleocapsid gene (Lai & Cavanagh 
1997).  
 
1.4.1.1 Current Knowledge on Accessory Genes and Accessory 
Proteins of Feline Coronaviruses 
Based on sequence comparisons, FCoV ORF 3a is homologous to CCoV ORF 3a 
and TGEV ORF 3a (Narayanan et al. 2008a). FCoV ORF 3a encodes a 72-amino 
acid (aa)-long protein without any known function. This protein is supposedly 
expressed from subgenomic mRNA 3 (sg mRNA 3) (Dye & Siddell 2005; Tekes et al. 
2008). However, the expression of this protein in FCoV-infected cells has not been 
demonstrated yet. 
The only known homolog of FCoV ORF 3b is CCoV ORF 3b (Narayanan et al. 
2008a). In the FCoV genome ORF 3b overlaps with ORF 3a and is suggested to 
encode a 9 kDa protein of unknown function. It is believed that 3b protein is 
translated by a noncanonical mechanism from sg mRNA 3. Thus far, expression of 
the 3b protein in FCoV-infected cells has not been shown.  
FCoV ORF 3c is homologous to CCoV ORF 3c, TGEV ORF 3b and ORF 3 of all 
other alphacoronaviruses (Narayanan et al. 2008a). It is predicted to encode a 238 
aa-long membrane protein with three transmembrane domains. The predicted 
topology of 3c protein resembles the topology of the M protein and SARS-CoV 3a 
protein (Narayanan et al. 2008b; Oostra et al. 2006). Similar to 3a and 3b, the 
expression of the 3c protein in FCoV-infected cells has not been demonstrated so 
far. It is also not known, whether 3c is expressed from the sg mRNA 3, like 3a and 
3b proteins, or from a different, so far unidentified sg mRNA. The existence of a 
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separate sg mRNA for 3c protein is plausible, since a TRS or a highly similar 
sequence is present upstream of the 3c start codon in most FCoV isolates. 
Sequence comparison of FECVs and FIPVs revealed that over 80% of FIPVs 
contain mutations in this gene leading to a truncated 3c, whereas FECVs possess an 
intact one. Accordingly, it has been suggested that 3c protein is essential for viral 
replication in the gut, but dispensable for replication in monocytes (Chang et al. 
2010). Homologs of FCoV 3c protein conserved in PEDV and HCoV-229E were 
reported to be incorporated into virions and function as ion channels (Wang et al. 
2012; Zhang et al. 2014). 
FCoV ORF 7a is homologous to CCoV ORF 7a and TGEV ORF 7 (Narayanan et al. 
2008a). 7a protein is expected to be translated from sg mRNA 7 to generate a 101 
aa-long protein (9 kDa) with an N-terminal signal sequence and a C-terminal 
transmembrane domain (Haijema et al. 2007). However, the expression of 7a in 
FCoV-infected cells has not been shown so far. 7a protein fused at the C-terminus 
with a GFP tag expressed from a plasmid construct was shown to co-localize with 
the endoplasmic reticulum (ER) and Golgi apparatus (Dedeurwaerder et al. 2014). 
This construct was then used to express 7a-GFP fusion protein in cells infected with 
recombinant FCoV where ORF 7 was deleted. These experiments led to the 
conclusion that 7a protein functions as a counteragent of IFN-α induced antiviral 
responses (Dedeurwaerder et al. 2014).  
FCoV ORF 7b is homologous only to CCoV ORF 7b. It is the only FCoV encoded 
accessory protein, for which expression was demonstrated in infected cells. 
Furthermore, FCoV 7b-specific antibodies have been detected in sera obtained from 
infected cats indicating that 7b protein is produced in vivo (Herrewegh et al. 1995; 
Kennedy et al. 2008; Lemmermeyer et al. 2016; Vennema et al. 1992). Herrewegh et 
al. (1995) reported that deletions in FCoV ORF 7b occur during passages of the 
virus in vitro. These mutations are probably due to cell culture adaptation and lead to 
loss of virulence in vivo. 7b is expressed from sg mRNA 7, but the exact translation 
mechanism of this ORF remains to be determined. Most of the present knowledge 
on 7b protein originates from a study conducted in the early 1990s (Vennema et al. 
1992). The authors identified the 7b protein in FCoV-infected cells using sera from 
infected cats. Furthermore, they expressed 7b protein from a plasmid in vaccinia 
virus-infected HeLa cells. These experiments showed that 7b is a secreted 
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glycoprotein (26 kDa). Localization of 7b protein in the ER was supported by 
treatment with Endoglycosidase H, which is able to cleave off high-mannose 
oligosaccharides present on the proteins in the ER, but not the complex glycan 
structures that are formed in the Golgi apparatus. The authors also suggested that 
the C-terminal KTEL motif acts as a KDEL-like endoplasmic reticulum (ER) retention 
signal that slows down 7b protein secretion. Vennema et al. (1992) showed that 
mutation of KTEL to KTEV in 7b protein led to enhanced secretion of the protein, 
while substitution of the KTEL with KDEL motif resulted in complete ER retention 
with no detectable secretion.  
 
1.4.1.2 FCoV Accessory Genes/Proteins Studied by Reverse 
Genetics 
Using reverse genetics, ORF 3, ORF 7 or both ORFs were deleted from the highly 
virulent serotype II FIPV strain 79-1146. Although the growth characteristics of the 
recombinant viruses were indistinguishable from that of the parental virus in vitro, 
they were unable to induce FIP in vivo. These results suggest that the accessory 
proteins are dispensable for viral replication in vitro, but important for the virulence in 
vivo (Haijema et al. 2004).  
Another study was performed using the same recombinant viruses to infect 
peripheral blood monocytes (Dedeurwaerder et al. 2013). It was shown that only the 
parental virus (serotype II FIPV strain 79-1146) and the virus with deleted ORF 3 led 
to replication in monocytes, but not viruses with deleted ORF 7 or both ORFs. 
Accordingly, it was suggested that ORF 7 is necessary for FIPV replication in 
monocytes (Dedeurwaerder et al. 2013). 
Influence of ORF 3 on viral replication in vivo was studied using the serotype II FIPV 
strain DF2 (Balint et al. 2012; Balint et al. 2014a; Balint et al. 2014b). In this strain, a 
deletion in ORF 3 results in truncated ORFs 3a and 3c and complete loss of ORF 3b. 
Using a reverse genetic system based on a bacterial artificial chromosome (BAC), 
ORF 3 was restored. Both the parental and the recombinant virus with restored ORF 
3 showed similar growth characteristics in established cell lines. However, replication 
of the parental virus in peripheral blood monocytes was significantly higher 
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compared to the recombinant virus with complete ORF 3, suggesting that the 
deletion in ORF 3 promotes efficient virus replication in monocytes. Furthermore, the 
authors proposed that an intact ORF 3 is essential for the virus replication in the 
intestine, but is dispensable for the replication in monocytes (Balint et al. 2014a; 
Balint et al. 2014b). 
 
1.5 N-linked Protein Glycosylation 
Glycosylation is a common post-translational modification, in which sugar moieties 
are added to proteins and lipids in reactions catalyzed by glycosyltransferases 
(Lodish et al. 2000; Varki et al. 2009). Glycosylation plays various structural and 
functional roles in cells and viruses (Varki et al. 2009). It was shown that 
glycosylation of viral proteins can influence infectivity (Luo et al. 2015; Stern & 
Sefton 1982), pathogenicity of viruses (de Brogniez et al. 2015; Kariwa et al. 2013) 
and is important for viral assembly (Zai et al. 2013). Moreover, masking of epitopes 
through glycosylation was described as a common strategy for viruses to avoid 
immune recognition (Alvarado-Facundo et al. 2016; Nelson et al. 2016; Rizzo et al. 
2016; Skehel et al. 1984; Townsley et al. 2015). 
The number of attached monosaccharide units can vary from only one to formation 
of complex, highly branched structures called glycans (McDonald et al. 2016). 
Glycosylation occurs in the lumen of the endoplasmic reticulum (ER) as well as in 
the lumina of the cis-, medial- and trans-Golgi cisternae (Lodish et al. 2000). Since 
the localization of different enzymes involved in glycosylation varies between these 
compartments, the presence of certain sugar moieties on a glycosylated protein 
indicates its subcellular localization (Lodish et al. 2000; McDonald et al. 2016; 
Nilsson et al. 2009; Stanley 2011). Five classes of glycosylation were identified so 
far: N-linked glycosylation, O-linked glycosylation, glypiation, C-mannosylation and 
phosphoglycosylation. 
N-linked glycosylation is the most common type of glycosylation and more than 50% 
of all eukaryotic proteins are N-glycosylated (Schwarz & Aebi 2011; Spiro 2002). 
During this process, glycans are covalently bound to the carboxamido nitrogen on 
asparagine residues. Enzymes involved in these processes are conserved across 
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species (Trombetta 2003). N-glycosylated proteins can possess large and 
extensively branched glycans that undergo four separate processing events. The 
initial two steps (glycan precursor assembly and its attachment to a target protein) 
occur identically for all proteins, while protein-specific differences manifest during 
subsequent trimming and glycan maturation (Trombetta 2003). 
The glycan precursor that is attached co-translationally to a target protein consists of 
14 sugar residues. These sugars moieties are added consecutively onto dolichol, a 
polyisoprenoid lipid carrier embedded in the ER membrane. Following addition of the 
first 7 residues to dolichol in the cytoplasm, the entire complex is transported into the 
lumen of the ER, where the glycan precursor is completed (Burda & Aebi 1999; 
Dean 1999). In the ER, oligosaccharyltransferase (OST) recognizes the Asn-X-
Ser/Thr motif in the protein and attaches the glycan precursor to the carboxamido 
nitrogen on the aspargaine residue. In the recognized motif, X can be any amino 
acid except for proline (Marshall 1972). 
Trimming of the oligosaccharides is achieved by hydrolysis and occurs both in the 
ER and Golgi apparatus. Glycan trimming in the ER is used to monitor proper protein 
folding. The properly folded glycoprotein is then transported to the Golgi where it 
undergoes further maturation (Ellgaard & Helenius 2003; Roth 2002). In case of 
incorrect folding, the protein is transported out of the ER, deglycosylated and 
delivered to ER-associated degradation (ERAD) (Ermonval et al. 2001; Frenkel et al. 
2003; Hosokawa et al. 2003; Kitzmuller et al. 2003). 
Glycan processing in the Golgi involves trimming and addition of sugars by specific 
enzymes in different cisternae of the Golgi (Nilsson et al. 2009). Two different final 
glycan structures exist. While high-mannose oligosaccharides consist of multiple 
mannose residues, complex oligosaccharides contain multiple sugar types (N-
acetylglucosamine, galactose, N-acetylneuraminic acid and fucose). Some 
glycoproteins have hybrid oligosaccharides with a combination of both structures 
(Stanley 2011).  
Since the steps of glycosylation occur in different cellular compartments, the 
subcellular localization of glycoproteins can be investigated by applying various 
glycosidases. While PNGase F completely removes complex glycan structure from 
proteins, Endo H is unable to cleave off these structures that are formed beyond the 
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cis-Golgi. Thus, the conversion of a glycoprotein from the Endo H-sensitive to the 
Endo H-resistant form is a hallmark of arrival in the medial-Golgi compartment (Balch 
& Keller 1986).  
 
1.6 Aims of the Study 
Feline coronaviruses (FCoVs) are important pathogens that infect members of the 
family Felidae worldwide. Based on pathogenesis, FCoVs are divided into two 
biotypes. FECV causes mild symptoms, while FIPV leads to a lethal disease (FIP). 
There is accumulating evidence that accessory genes/proteins of FCoVs play an 
important role in virulence and may be important for establishment of persistent 
infection. However, lack of proper immunological tools thus far, limited the 
characterization of FCoV-encoded accessory proteins. 
The FCoV-encoded accessory protein 7b was shown to be expressed in FCoV-
infected tissue culture cells as well as in infected cats. 
To study the expression and subcellular localization of 7b protein, a recombinant 
serotype II FIPV strain 79-1146 (rFIPV) expressing the non-glycosylated form of 7b 
protein was generated by use of a vaccinia virus-based reverse genetic system. In 
rFIPV-infected CRFK cells, 7b protein was characterized by Western blot and 
confocal microscopy using anti-7b monoclonal antibody.  
Next, the mature, glycosylated form of 7b protein was studied in feline cells using a 
set of rFIPVs expressing flag-tagged 7b protein generated by vaccinia virus-based 
reverse genetics. Expression and subcellular localization of the flag-tagged, 
glycosylated form of 7b protein in FIPV-infected cells was analyzed with Western blot 
and confocal microscopy using anti-flag mAb.  
Finally, we aimed to investigate the influence of the C-terminal KTEL motif of 7b 
protein on its subcellular localization/trafficking in infected feline cells.  
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2 Materials & Methods 
 
2.1  Materials 
 
2.1.1 Cells 
2.1.1.1 Eukaryotic Cells 
BHK-21 (Baby Hamster Kidney)     ATCC number: CCL-10 
BHK-FIPV-N: (BHK cells expressing N protein of Institute of Virology, Giessen 
 FIPV79-1146 - Tet-On system) 
CRFK (Crandell Reese feline kidney)   Institute of Virology, Giessen 
CV-1 (monkey kidney cells)    ATCC number: CCL-70 
D980R gift from G. L. Smith, Imperial 
College, London, UK 
Fc3Tg (Feline tongue)     Institute of Virology, Giessen 
FCWF-4 (felis catus whole fetus)    Institute of Virology, Giessen 
 
2.1.1.2 Prokaryotic Cells 
E. coli strain HB101 K-12     Institute of Virology, Giessen 
 
2.1.2 Viruses 
FCoV 79-1146  gift from R.J. de Groot, 
Utrecht 
vrFIPV   Institute of Virology, Giessen 
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2.1.3 Plasmids 
pGPT-1      (Hertzig et al. 2004) 
pGEM-T      Promega 
 
2.1.4 Enzymes 
Endo H      New England Biolabs (NEB) 
Phusion DNA polymerase    Thermo Scientific 
PNGase F      New England Biolabs (NEB) 
Proteinase K      Roche 
Restriction enzymes    New England Biolabs (NEB) 
Expand Reverse transcriptase   Roche 
RNase-free RQ1 DNase    Promega 
Taq DNA polymerase    GeneCraft Germany 
T4 DNA ligase     New England Biolabs (NEB) 
Trypsin      Invitrogen  
 
2.1.5 Antibodies  
Primary antibodies: 
anti-7b 14D8 mAb mouse monoclonal antibody detecting 7b protein of 
FCoVs, Institute of Virology, Giessen 
anti-Flag® M2 mouse monoclonal antibody detecting flag tag 
(DYKDDDDK), Sigma 
anti-Giantin rabbit polyclonal antibody detecting Golgi protein Giantin, 
Abcam 
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anti-PDI rabbit polyclonal antibody detecting ER Protein Disulfide 
Isomerase, Sigma 
Secondary antibodies: 
Goat anti-mouse IgG-PO Horseradish Peroxidase-conjugated, 
Dianova 
Goat anti-mouse IgG Alexa Fluor® 488  Invitrogen 
Goat anti-rabbit IgG Alexa Fluor® 594  Invitrogen 
 
2.1.6 Chemicals 
Acrylamide, bisacrylamid solution 40%  Carl Roth  
Agarose      Carl Roth 
Alkaline phosphatase    Roche 
6-aminocaproic acid    Sigma-Aldrich 
Ampicillin      Serva 
APS (Ammonium persulfate)   Sigma-Aldrich 
Bacto Agar      Becton Dickinson 
BSA (Bovine serum albumin)   Roche 
Chloroform      Carl Roth 
CMC (Carboxymethyl cellulose)   Sigma-Aldrich 
Cycloheximide (CHX)    Sigma-Aldrich 
Developer solution for X-ray films   Devomed 
DMSO (Dimethyl sulfoxide)   Carl Roth 
dNTPs (Deoxynucleoside triphosphate)  Invitrogen   
EDTA (Ethylenediaminetetraaceticacid)  Carl Roth 
Ethanol      Carl Roth 
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Ethidium bromide     Fluka 
FCS (fetal calf serum)    Biochrom 
Fixer solution for X-ray films   Devomed 
Formaldehyde (37%)    Carl Roth 
GeneRuler 1 Kb Plus    Thermo Scientific 
Glycerin (87%)     Carl Roth 
G418-Sulfate      Calbiochem 
Hypoxanthine     Sigma-Aldrich 
Isopropanol      Carl Roth 
Lithium chloride precipitation solution  Ambion 
Lipofectamine 2000     Invitrogen 
β-mercaptoethanol     Sigma-Aldrich 
MOPS      Fluka 
Mowiol 4-88      Sigma-Aldrich 
Mycophenolic acid (MPA)    Sigma Aldrich 
NaCl (sodium chloride)    Carl Roth 
NP-40 (Nonident® P40)    Fluka 
Page Ruler Prestained Protein Ladder  Thermo Scientific 
PCR 10x buffer     GeneCraft Germany 
Pefablock SC     Sigma-Aldrich 
Penicillin/Streptomycin     Sigma-Aldrich 
Phenol      Carl Roth 
Ponceau S solution     Sigma-Aldrich 
Powdered milk     Frema 
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Protein G-SepharoseTM4 Fast Flow  GE Healthcare 
Puromycin      Alexis Biochemicals 
RNA cap analog     New England Biolabs (NEB) 
RNA Gel Loading Dye    Ambion 
RNaseOUT      Invitrogen 
RNA storage solution    Ambion 
Roti® Block A (10X)     Carl Roth 
Roti® Block K (10X)     Carl Roth 
Roti®ImmunoBlock     Carl Roth 
Saccharose      Carl Roth 
SDS (sodium dodecyl sulfate)   AppliChem 
Sodium deoxycholate    Fluka 
TEMED (Tetramethylethylenediamine)  Fluka 
6-Thioguanine      Sigma-Aldrich 
Tricine      Carl Roth 
Tris       Carl Roth 
Triton X-100      Sigma-Aldrich 
Trypan blue      Serva 
Tween-20      Sigma-Aldrich 
Western Lightning Plus-ECL, Enhanced  Perkin Elmer 
Chemiluminescence Substrate 
Xanthine      Sigma-Aldrich 
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2.1.7 Kits 
Expand Reverse Transcriptase Kit   Roche 
GenEluteTM Gel Extraction Kit    Sigma-Aldrich 
GenEluteTM PCR Clean-up Kit    Sigma-Aldrich 
GenEluteTM Plasmid Miniprep Kit    Sigma-Aldrich 
pGEM-T Vector System     Promega 
peqGOLD Total RNA Kit     PEQLAB 
RiboMaxTM Large Scale RNA Production Systems Promega  
 
2.1.8 Culture Media 
 
2.1.8.1 Bacterial Culture Media 
LB-Medium 
10g NaCl, 10g Tryptone, 5g Yeast extract for 1l H2O, pH 7.5  
LB-Plates 
1.5 % Bacto Agar in LB-Medium, 100 µg/ml Ampicillin 
 
2.1.8.2 Cellular Culture Media 
CCM 34 (prepared by the medium kitchen of 
the Institute of Virology, Giessen) 
4.5 g/l DMEM powder, 0.0178 g/l L-
Alanine, 0.7 g/l Glycine, 0.075 g/l L-
Glutamic acid, 0.025 g/l Proline, 0.1 
mg/l Biotin, 0.025 g/l Hypoxanthine, 
3.7 g/l NaHCO3, sterile filtered, 
storage at 4 °C 
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Minimal Essential Medium (MEM) Eagle  Sigma 
 
Negative selection medium 
 
MEM, 1 µg/ml 6-TG, 10% FCS (v/v), 
50.000 UI/ml Penicillin G, 50 mg/ml 
Streptomycin sulfate 
 
Opti-MEM I      Gibco 
 
Positive selection medium 
 
MEM, 250 µg/ml Xanthine, 25 µg/ml 
MPA, 15 µg/ml Hypoxanthine, 10% 
FCS (v/v), 50.000 UI/ml Penicillin G, 
50 mg/ml Streptomycin sulfate 
 
Cell culture media for 
BHK-21            CCM34 450 ml + FCS 50 ml + Penicillin/Streptomycin 1ml 
BHK-FIPV-N CCM34 450 ml + FCS 50 ml + Penicillin/Streptomycin 1ml 
+ G418 (100 µg/ml) + Puromycin (2µg/ml) 
CRFK  CCM34 450 ml + FCS 50 ml + Penicillin/Streptomycin 1ml 
CV-1 MEM 500 ml + FCS 50 ml + Penicillin/Streptomycin 1ml 
D980R  MEM 500 ml + FCS 50 ml + Penicillin/Streptomycin 1ml 
Fc3Tg CCM34 450 ml + FCS 50 ml + Penicillin/Streptomycin 1ml 
FCWF-4 CCM34 450 ml + FCS 50 ml + Penicillin/Streptomycin 1ml  
 
Supplements for cell culture 
Penicillin/Streptomycin 500X 50.000 UI/ml Penicillin G, 50 mg/ml Streptomycin 
sulfate 
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Trypsin solution 8 g/l NaCl, 0.2 g/l KCl, 1.44 g/l Na2HPO4 × 2H2O, 
2.5 g/l Trypsin, 16 mg/l Phenol red, 3.3 mM EDTA 
in PBS 
 
2.1.9 Buffers and Solutions 
All buffers and solutions, if not stated otherwise, were prepared in double distilled 
water (ddH2O).  
A buffer (10X) 100 mM Tris/HCl, 10mM EDTA, pH 
7.5; sterile filtered, 4 °C 
 
Anode buffer for SDS-PAGE   0.2 M Tris/HCl, pH 8.9 
 
Antibody dilution buffer 1% BSA (w/v), 0.1% Triton-X100 
(v/v) in PBS 
 
APS for SDS-PAGE gel casting   10% APS (w/v) in ddH2O, -20 °C 
 
Blocking buffer for immunofluorescence  10% Roti®ImmunoBlock (10X) in 
PBS 
 
Blocking buffer for Western blot   5% powdered milk (w/v) in PBST 
 
Cathode buffer for SDS-PAGE 100 mM Tris/HCl, 100 mM Tricine, 
0.1% SDS (w/v), pH 8.25 
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DNA loading buffer 2.5 ml Orange G 1%, 3.5 ml Glycerin 
(87%), 4.0 ml H2O, 4 °C 
 
DNase buffer (10X) 400 mM Tris, 100 mM MgSO4, 10 
mM CaCl2, pH 8.0, sterile filtered 
 
dNTP mix (25 mM) for PCR 25 mM of dATP, dCTP, dGTP, dTTP; 
- 20 °C 
 
Jagow gel buffer 3 M Tris/HCl, 0.3% SDS (w/v),  
pH 8.45  
 
MOPS buffer (10X) 200 mM MOPS, 50 mM sodium 
acetate (anhydrous), 10 mM EDTA, 
pH 7.0; sterile filtered and 
autoclaved, 4 °C  
 
Mowiol mounting media for 
immunofluorescence 
 
6 g Glycerin and 2.4 g Mowiol 4-88 
were dissolved in 6 ml ddH2O, 12 ml 
of Tris/HCl (200 mM), pH 8.5 was 
added and centrifuged at 5000 × g for 
15 min. 0.1 g 1,4-
Diazabicyclo(2.2.2)octane (DABCO) 
per 1 ml medium was added before 
use; -20 °C 
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PBS 0.8 g/l NaCl, 0.2 g/l KCl, 0.2 g/l 
KH2PO4 × H2O, 1.15 g/l Na2HPO4 × 
H2O dissolved in ddH2O, autoclaved 
and stored at 4 °C 
 
PBST       PBS with 0.1% Tween-20, 4 °C 
 
Permeabilization solution    1% (v/v) Triton-X100 in PBS, 4 °C 
 
Proteinase K buffer (2X) 400 mM NaCL, 200 mM Tris/HCl, 10 
mM EDTA, 0.5% SDS (w/v), pH 7.5; 
sterile filtered 
 
PVDF transfer buffers 
Anode buffer I    300 mM Tris 
Anode buffer II    25 mM Tris 
Cathode buffer    6-aminocaproic acid 40 mM 
 
Radioimmunoprecipitation assay (RIPA) 
buffer  
150 mMNaCl, 1% NP-40, 0.5% 
sodium deoxycholate (w/v), 0.1% 
SDS (w/v), 50 mMTris, pH 8.0, 4 °C 
 
SDS-PAGE sample loading buffer (4X) 8% SDS (w/v), 40% Glycerin (v/v), 
0.01% Bromophenol blue (w/v),  
-20 °C 
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TFB-I  30 mM KOAc, 100 mM RbCl, 10 mM 
CaCl2, 50 mM MnCl2, 15 % Glycerin 
(v/v), pH 5.8 established with acetic 
acid, sterile filtered 
 
TFB-II 10 mM MOPS, 10 mM RbCl, 75 mM 
CaCl2, 15 % Glycerin (v/v), pH 6.5 
established with KOH, sterile filtered 
 
Tris-acetate-EDTA (TAE) buffer for agarose 
gel electrophoresis (50X) 1l 
242 g Tris, 57.1 ml glacial acetic acid, 
5 mM EDTA, pH 8.0 
 
Trypan blue Solution            0.25% Trypan blue (w/v), 0.15 M NaCl 
 
Western blot transfer buffers 
Anode buffer (1X) 20% Methanol (v/v), 10 % Roti® Blot 
A (10X) 
Cathode buffer (1X) 20% Methanol (v/v), 10 % Roti® Blot 
K (10X) 
 
2.1.10 Consumables 
Cell culture plates and dishes Nunc, Thermo Scientific, 
Greiner Bio-One 
Cell lifter Corning Incorporated 
Centrifuge tubes (15 and 50 ml) Greiner Bio-One 
Cryotubes Thermo Scientific 
Electroporation cuvettes     VWR 
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Filter paper       Whatman 
Glass cover slips      MAGV 
Glass pipettes       MAGV 
MagNa Lyser Green Beads    Roche 
Microscope slide      Carl Roth 
Nitrile gloves       VWR 
Nitrocellulose membrane     GE Healthcare 
Pipette tips       Nerbe 
Plastic pipettes (10 and 25 ml)    Thermo Scientific 
PVDF membrane      Carl Roth 
Reaction tubes      Eppendorf 
Syringe filters (0.2 µm pore size)    Thermo Scientific 
Ultracentrifuge tubes     Beckman Coulter  
X-ray films       Advansta 
 
2.1.11 Equipment 
Bacterial culture shaker K15/500    Noctua 
Cell culture incubator (model C200)   Labotect 
Class II biological safety cabinet    Thermo Scientific 
 MSC-Advantage 
Electrophoresis power cell     Biometra 
Freezer (-20 °C)      Liebherr 
Freezer (-80 °C) Hera Freeze    Thermo Scientific 
Freezing container       Nalgene 
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Fridge        Liebherr 
Gel documentation system Rainbow   Intas 
Gene Pulser Electroporator    Bio-Rad 
Heat block  workshop of the Institute of  
Virology, Giessen 
Laser scanning confocal microscope TCS SP5  Leica 
Light microscope DM-IL     Leica 
Liquid nitrogen tank RS Series    Tec-Lab 
MagNa Lyser homogenizer    Roche 
NanoVue nucleic acid concentration measuring  GE Healthcare 
 device 
Neubauer Improved cell counting chamber  Marienfeld 
PCR thermal cycler (model 2720)    Applied Biosystems 
pH-meter       Hanna Instruments 
Pipetboy       Integra Biosciences 
Semi dry transfer system     Bio-Rad 
Single channel pipettes      Brand 
Sonopuls HD200 probe sonicator    Bandelin 
Sonorex RK 52 ultrasonic bath    Bandelin 
Tabletop centrifuge Fresco 21    Thermo Scientific 
The Sturdier SDS-PAGE gel system   Hoefer Scientific Instruments 
Ultracentrifuge model L8-60M    Beckman Coulter 
Vacuum pump      Saskia 
Water bath       Memmert 
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Weighing scale PCB     KERN 
 
2.1.12 Synthetic DNA Oligonucleotides 
 
2.1.12.1 Oligonucleotides for FCoV 79-1146 Genome 
The numbers in the oligonucleotide name (Oligo) refer to its position in the FCoV  
79-1146 genome, GenBank Accession number NC002306. Oligonucleotides used 
for PCR to analyze the integrity of FCoV cDNA integrated into vaccinia virus genome 
(2.2.6.1.4) are listed in Table 2. The rest of FCoV 79-1146-specific oligonucleotides 
are listed in Table 3. 
 
PCR 
fragment 
number 
Oligo Nucleotide sequence (5’ → 3’) Orient. 
1 
79-25-F ACTTTTAAAGTAAAGTGAGTGTAGC + 
79-3300-R ACACTTGCATCAGAATCGCTTTTGTC - 
2 
79-3505-F 
GAGCAACTTTCCTCAGTAGAAAAAAA
AGATGAAGTCTCTGC 
+ 
79-6500-R TTAAGTGCGAGAACTGCCTTAAAAA - 
3 
79-6300-F ATGGAATAGAGTTATACAATTGTCG + 
79-9020-R 
AACACCACTAGGCTGTGCCATTTTCT
CAATCCGG 
- 
4 
79-9020-F 
CCGGATTGAGAAAATGGCACAGCCT
AGTGGTGTT 
+ 
79-11300-R AAACTATGCATAGCTGAAACTATTT - 
5 79-11200-F TTTGAGCGAGAAGCTTCCGTGCAAA + 
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79-13750-R CTCTGTTGTAGCGGTAATAATTGAAG - 
6 
79-13750-F-
XhoI 
CTCGAGCCGCTACAACAGAGTCACA
GTACTTG 
+ 
79-16800-R-
BsmBI 
CGTCTCTGTAGATAACATAATCATAC
TCACTACCCTGC 
- 
7 
79-16800-F-
BsmBI 
CGTCTCTCTACACACAGACTTCCGAT
ACACAGC 
+ 
79-18500-R 
GGAGTGCTTTGCTATTAACAAAACCG
TGCC 
- 
8 
79-18100-F-
BamHI 
GGATCCGGAACTGCAATGTAGACAT
GTACCCAGAG 
+ 
79-21850-R-
NotI 
GCGGCCGCCAACTTGTACTAATGCT
TCAGTATACGATG 
- 
9 
79-21300-F GTTCCACTTTTGTTAGTGGCAGGTT + 
79-23900-R CATTAAGTGCTGTAAGTCTACCTGT - 
10 
79-23100-F TTGAACAAGCACTTGCAATGGGTGC + 
79-26075-R-
SacI 
GAGCTCTTAATAACATTTAGCAATGC
TATTG 
- 
11 
79-24303-F-
XhoI 
CTCGAGGGGTGTGATGTGTTGTTTG
TCAAC 
+ 
79-27150-R 
GATCCTTGTTCGAGGGTAATGGGGT
TGTAG 
- 
12 
79-26990-F-
SacII 
CCGCGGGTAACATATGGTGTAACTA
AACTTTC 
+ 
79-29355-R-
SacI 
GTATCACTATCAAAAGGAAAATTTT 
- 
Table 2. Oligonucleotides used for the PCR to analyze the integrity of FCoV cDNA (2.2.6.1.4). 
Orient., orientation of the oligonucleotide. 
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Oligo Nucleotide sequence (5’ → 3’) Orient. 
79-27650-F-XhoI 
CTCGAGGAGAACGTAGTGATTCCAAACCTA
G 
+ 
79-28130-R-EcoRI 
GAATTCCAATCATCTCAACGTGTGTGTCATC
A 
- 
79-28300-F TGTAAATTGTTTGCAGCTTTTGAAA + 
79-28457-F-BsmBI 
CGTCTCAAATAACATCATGATTGTTGTAATCC
TTGTGTGT 
+ 
79-28462-R-BsmBI 
CGTCTCAATCATGATGTTAAAATAATGCACC
CAACAATG 
- 
79-28485-R 
CGTCTCTGTCATCCTTGTAATCAGCTTTAATT
CCATTAGCCAAAAAGATA 
- 
79-28534-F 
CGTCTCATGACGACGATAAGACTGCTGTGC
AAAATGACCTTC 
+ 
79-28653-F-QC-N68S CGAAGGTTTCTCATGCACATGGCC + 
79-28653-R-QC-N68S GGCCATGTGCATGAGAAACCTTCG - 
79-29049-R-7bF 
CGTCTCTGTCATCCTTGTAATCTAACTCAGTT
TTATGATGTTGGTTGAT 
- 
79-29068-F-AAEL 
AACCAACATCATGCAGCTGAGTTATAAGGCA
ACCCGA 
+ 
79-29068-R-AAEL 
TTGCCTTATAACTCAGCTGCATGATGTTGGT
TGATTTTG 
- 
79-29071-F-KDEL 
AACCAACATCATAAAGATGAGTTATAAGGCA
ACCC 
+ 
79-29071-R-KDEL 
GTTGCCTTATAACTCATCTTTATGATGTTGGT
TGATT 
- 
79-29074-F-AAAA ACATCATGCAGCTGCTGCATAAGGCAACCC + 
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GATGTCT 
79-29074-R-AAAA 
GGGTTGCCTTATGCAGCAGCTGCATGATGTT
GGTTGAT 
- 
79-29077-F-KTE 
CATCATAAAACTGAGTAAGGCAACCCGATGT
CTA 
+ 
79-29077-R-KTE 
CATCGGGTTGCCTTACTCAGTTTTATGATGT
TGG 
- 
79-29077-F-KTEV 
CATAAAACTGAGGTTTAAGGCAACCCGATGT
CTA 
+ 
79-29077-R-KTEV 
CGGGTTGCCTTAAACCTCAGTTTTATGATGT
TG 
- 
79-29082-F-7bF 
CGTCTCATGACGACGATAAGTAAGGCAACC
CGATGTCTAAAACTGGTC 
+ 
79-29085-F-SacII 
CCGCGGCAACCCGATGTCTAAAACTGGTCT
TT 
+ 
Table 3. FCoV 79-1146 specific oligonucleotides used for plasmid generation (2.2.3.5). Orient., 
orientation of the oligonucleotide. 
 
2.1.12.2 Other Oligonucleotides 
Oligo Nucleotide sequence (5’ → 3’) Orient. 
M13 TGTAAAACGACGGCCAG + 
M13r CAGGAAACAGCTATGAC - 
GPT-250s GAAGGCGATGGCGAAGGCTTCATCG + 
GPT-300as AGTGCGCTTTTGGATACATTTCACG - 
VVL1 CTTAACGATGTTCTTCGCAGATG - 
Table 4. Oligonucleotides used for sequencing. Orient., orientation of the oligonucleotide. 
  
 
- 40 - 
 
2.2 Methods 
 
2.2.1 Eukaryotic Cells: Techniques 
 
2.2.1.1 General Techniques 
All cell culture techniques were performed under sterile conditions in class II 
biological safety cabinet. Cells were grown on cell culture dishes with the diameter of 
10 or 15 cm at 37 °C, 5% CO2 in an incubator with humidity of around 96%. Cell 
lines were maintained in cell culture media as described above (section 2.1.8.2). 
Passaging cells encompassed removal of the media, washing step with 2-3 ml 
Trypsin and 2-5 min incubation with Trypsin in the cell culture incubator. After the 
cells have detached from the surface of the culture dish, they were resuspended in 
fresh culture media and a portion of them was seeded on a new dish.  
 
2.2.1.2 Cell Counting 
In order to determine the number of viable cells in a culture, the cells were first 
tripsinized (2.2.1.1) and then diluted 5X with the Trypan blue solution. Diluted cells 
were applied to the Neubauer Improved cell counting chamber, counted under the 
light microscope and the final cell number was determined from the equation: 
𝑛 × 5 × 10000 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠/𝑚𝑙 
n is the average number of cells counted in 4 big squares of the chamber.  
 
2.2.1.3 Cryopreservation and Storage of Cells 
All available cell lines were cryopreserved for longer storage. Cells were first 
tripsinized (2.2.1.1) and centrifuged at 1400 rpm, 4 °C for 5 min. Cell pellet was 
resuspended in 3 ml FCS with 10% DMSO and aliquoted to 3 cryotubes. Cryotubes 
were then transferred to a freezing container and stored in a -80 °C freezer for two 
days. Subsequently, frozen cells were stored in a liquid nitrogen tank. 
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2.2.1.4 Cell Infection 
Determined number of cells (2.2.1.2) was seeded prior to virus infection. After the 
cells have attached, the medium was removed and cells were washed with FCS-free 
medium. Virus suspension with a defined MOI (multiplicity of infection) was used for 
the infection. MOI is described with a following equation:  
MOI =
𝑚𝑙 𝑣𝑖𝑟𝑢𝑠 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 × 𝑣𝑖𝑟𝑢𝑠 𝑡𝑖𝑡𝑒𝑟/𝑚𝑙
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑒𝑒𝑑𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
 
FCS-free medium was used to dilute the virus suspension to obtain the desired MOI. 
Cells were incubated in a cell culture incubator at 37 °C for 1 h. Following incubation, 
the virus suspension was removed, cells were washed with FCS-free medium and 
overlaid with fresh medium.  
 
2.2.1.5 Indirect Immunofluorescence Assay 
Indirect immunofluorescence assay was used to determine the localization of 7b 
protein in serotype II FIPV strain 79-1146 infected cells. Microscope cover slips were 
disinfected with 70 % ethanol and washed twice with PBS. CRFK, FCWF-4 or Fc3Tg 
cells were counted (2.2.1.2) and seeded (1.2 ×105 cells/well) on the cover slips 
located in a 24-well cell culture plate. After the cells have attached to the cover slips 
(ca. 8 h), they were infected with a virus at an MOI of 1 (MOI=1) (2.2.1.4). 16 h p.i. 
(CRFK) or 10 h p.i. (FCWF-4, Fc3Tg) cells were fixed with 2 % paraformaldehyde for 
20 minutes at room temperature (RT). In experiments, where the ongoing protein 
synthesis was blocked, cycloheximide (CHX, 100 μg/ml final concentration) was 
added 2 hours before the cells were fixed. Following fixation, cells were washed 3 
times with PBS and permeabilized using 1 % Triton-X100 in PBS for 5 minutes. After 
3 washing steps with PBS, residual binding sites were blocked with 10% 
Roti®ImmunoBlock (10X) in PBS for 10 minutes at RT. Cells were incubated with 
primary antibodies for 1 h at RT. Dilutions of the applied primary antibodies are 
described in Table 5. Following washing 3 times with PBS, cells were incubated with 
secondary antibodies (Table 5) for 1 h at RT. DNA was stained with 4’,6-diamidino-2-
phenylindole (DAPI, 66 μg/ml final concentration). Cells were then washed 3 times 
with PBS, cover slips were mounted with Mowiol medium and sealed using nail 
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polish. The preparations were visualized with Laser Scanning Confocal Microscope 
(Leica TCS SP5). 
 
Primary antibodies Dilution* 
anti-7b 14D8 mAb 1:3 
anti-Flag® M2 1:30.000 
anti-PDI 1:500 
anti-Giantin 1:200 
Secondary antibodies Dilution* 
Goat anti-mouse IgG Alexa Fluor® 488 1:1000 
Goat anti-rabbit IgG Alexa Fluor® 594 1:1000 
Table 5: Antibodies for Indirect Immunofluorscence Assay. *Antibodies were diluted in Antibody 
dilution buffer (2.1.9) 
 
2.2.1.6 Transfection of Eukaryotic Cells 
 
2.2.1.6.1 Chemical Transfection 
CV-1 cells were seeded on a 6-well plate (5 × 105 cells/well) and on the next day 
infected with an appropriate vaccinia virus (MOI = 1). 1 h after the infection, two 
tubes containing 250 μl of Opti-MEM were prepared. 10 μl of Lipofectamine 2000 
was added to one tube and 4 μg of plasmid DNA to the other. Following 5 min 
incubation at room temperature, plasmid DNA solution was added to the tube with 
Lipofectamine 2000 and incubated for 30 min. Virus suspension was removed from 
the cells 2 h p.i., cells were washed and overlaid with 1.5 ml Opti-MEM. The DNA-
Lipofectamine 2000 transfection mixture was added dropwise to the cells. Following 
5-6 h incubation in cell culture incubator, the transfection medium was removed and 
cells were overlaid with fresh MEM medium. 2-3 days after the infection/transfection, 
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the cells were harvested, centrifuged at 3000 rpm, 4 °C for 3 min and resuspended 
in 700 μl of MEM medium. Following three cycles of freezing in liquid nitrogen and 
thawing in an ultrasonic bath, the virus stock was used for positive or negative 
selection to generate recombinant vaccinia viruses (see section 2.2.6.1.2 and 
2.2.6.1.3). 
 
2.2.1.6.2 Physical Transfection (Electroporation) 
Electroporation (EP) was used to introduce in vitro transcribed rFIPV-RNA (2.2.4.3) 
into BHK-FIPV-N cells. BHK-FIPV-N cells were cultured on a dish (10cm diameter) 
and were induced with Doxycycline (1 μg/ml final concentration) 20 hours prior EP. 
Next day, the cells were tripsinized (2.2.1.1) and centrifuged at 1200 rpm, 4 °C for 4 
min. Medium was discarded and the cell pellet was resuspended in 10 ml PBS. 
Following second centrifugation step, the cell pellet (ca. 107 cells) was resolved in 
800 μl PBS and transferred into a pre-cooled electroporation cuvette. 10-20 μg of 
rFIPV-RNA was added to the cells. Electroporation was achieved with 2 pulses at 
1.5 kV, with 200 Ω resistance and 25 μF capacitance using BioRad Gene Pulser 
Electroporator. Electroporated cells were transferred into a 10 cm culture dish with 
fresh CCM34 medium. 107 FCWF-4 cells were mixed to the BHK-FIPV-N cells and 
incubated for 2 days (cocultivation).  
 
2.2.2 Prokaryotic Cells: Techniques 
 
2.2.2.1 Cultivation of Bacteria 
Escherichia coli (E.coli) strain HB101 K12 cells were cultivated overnight at 37 °C in 
LB-medium on a horizontal shaker. For selection of bacteria containing plasmid with 
Ampicillin resistance cassette, Ampicillin (100 μg/ml) was added to the LB-medium.  
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2.2.2.2 Preparation of Competent E. coli Cells 
2.5 ml LB-medium was inoculated with a single colony of E. coli strain HB101 K12 
grown on an LB-plate. Following overnight incubation at 37 °C, the overnight culture 
was diluted 1:100 in LB-medium containing 20 mM MgSO4 (250 ml) and grown until 
the optical density of the suspension measured at 590 nm (OD590) reached 0.4-0.6. 
The culture was centrifuged at 5000 rpm, 4 °C for 5 minutes. The cell pellet was 
resuspended in 100 ml ice-cold TFB-I buffer and incubated on ice for 5 min. 
Following second centrifugation, the cell pellet was resuspended in 10 ml TFB-II 
buffer and incubated on ice for 30 min. The cell suspension was then aliquoted (100 
μl/tube) and stored at -80 °C freezer.  
 
2.2.2.3 Transformation of Competent E. coli Cells 
Plasmid DNA was added to 50 μl of the competent E. coli HB101 K12 cell 
suspension (2.2.2.2) and the mixture was incubated on ice for 20 min. The cells were 
then submitted to heat shock at 42 °C for 45 sec. Following incubation on ice for 3 
minutes, 250 μl of LB-medium was added and the cell suspension was incubated at 
37 °C on a horizontal shaker for 30-60 min. Cells were then centrifuged at 5000 rpm 
for 3 minutes and resuspended in 100 μl of the supernatant. Transformed cell 
suspension was plated on an LB-plate and incubated overnight at 37 °C.  
 
2.2.3 Molecular Techniques – DNA 
 
2.2.3.1 Standard Techniques 
 
2.2.3.1.1 Polymerase Chain Reaction (PCR) 
The following protocol was used to generate PCR products for cloning (2.2.3.5) and 
for characterization of recombinant viruses (2.2.7.1):  
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Reagent Amount [μl] PCR cycles 
PCR buffer (10X) 5.0 Primary denaturation 94 °C, 3 min 
Forward primer (50 mM) 0.5 35 cycles of:  
Reverse primer (50 mM) 0.5 Denaturation  94 °C, 30 s 
dNTP mix 0.5 Annealing 50-60 °C, 30 s 
Taq polymerase 0.5 Elongation 72 °C, 1 min/kb 
ddH2O 40.5   
DNA template 2.5 Elongation  72 °C, 10 min 
Table 6. PCR standard protocol. 
 
2.2.3.1.2 QuickChange PCR 
The protocol below was used to introduce mutations into existing plasmid 
sequences. 
 
Reagent Amount [μl] PCR cycles 
PCR  HF buffer (5X) 10.0 Primary denaturation 94 °C, 3 min 
Forward primer (50 mM) 1 18 cycles of:  
Reverse primer (50 mM) 1 Denaturation  94 °C, 30 s 
dNTP mix 1 Annealing 56-63 °C, 45 s 
Phusion polymerase 0.5 Elongation 68 °C, 40 s/kb 
ddH2O 36   
Plasmid DNA 0.5 Elongation  68 °C, 10 min 
Table 7. QuickChange PCR standard protocol. 
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2.2.3.1.3 Digestion with Restriction Enzymes 
Restriction enzymes were used to control the result of a ligation (2.2.3.1.5) and to 
generate plasmids (2.2.3.5).  
pGEM-T-based plasmids purified with Miniprep Kit (2.2.3.3.1) were controlled by 
digesting with EagI restriction enzyme. For this purpose 200 ng of plasmid was 
incubated with 5U of EagI at 37 °C for 1 hour. The cleaved DNA was resolved by 
electrophoresis (2.2.3.4.1) using a 1% agarose gel.  
For the generation of plasmids, an insert from one plasmid was subcloned into 
another plasmid. To achieve that, both plasmids (4 μg each) were digested with the 
same set of restriction enzymes as recommended by the supplier.  
 
2.2.3.1.4 Dephosphorylation 
In order to prevent self-ligation of digested plasmids, the vectors were 
dephosphorylized. For this purpose, vectors after digestion with restriction enzymes 
(2.2.3.1.3) were incubated with 5 U of alkaline phosphatase (Roche) at 37 °C for 30 
min. 
 
2.2.3.1.5 Ligation 
Purified PCR products (2.2.3.2.2) were cloned into pGEM-T vector using pGEM-T 
Vector System Kit (Promega). This procedure utilizes adenines added by the Taq 
polymerase at the 3’ end of the PCR products. Linearised vector with complementary 
thymines was ligated with the PCR product in the presence of T4 DNA ligase. 
Ligation of products after restriction enzyme cleavage was performed in 10 μl final 
volume. Vector- and insert-DNA was mixed in 1:3 molar ratio. 1 μl of 10X T4 DNA 
ligase buffer and 0.5 μl T4 DNA ligase were added to the DNA mixture and the 
reaction was filled up to 10μl with ddH2O. Ligation was performed at 4 °C overnight. 
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2.2.3.2 DNA Purification 
 
2.2.3.2.1 Phenol/Chloroform Extraction with Ethanol Precipitation 
To extract the DNA from aqueous solution, same volume of Phenol was added. After 
mixing the two phases, the mixture was centrifuged at 13.000 rpm, 4 °C for 4 
minutes. The upper phase was pipetted into a new tube and mixed with an equal 
volume of Chloroform. Following centrifugation, upper phase was removed and 
mixed with 2.5 volume of 100 % ice-cold ethanol. Following 10 min incubation on ice, 
precipitated DNA was centrifuged at 13.000 rpm, 4 °C for 10 minutes and the 
supernatant was removed. The DNA pellet was washed with 200 µl 70 % ethanol 
and centrifuged for another 5 minutes. After repeating the washing step, DNA was 
resolved in 40 μl ddH2O. 
 
2.2.3.2.2 Purification of PCR products 
Purification of PCR products was performed using GenEluteTM PCR Clean-up Kit 
(Sigma-Aldrich) according to the manufacturer’s recommendations. 
 
2.2.3.2.3 Gel Extraction 
DNA resolved with agarose gel electrophoresis (2.2.3.4.1) was visualized using a UV 
table. DNA bands of interest were excised from the gel using a sterile scalpel and 
were purified using GenEluteTM Gel Extraction Kit (Sigma-Aldrich) according to the 
manufacturer’s recommendations. 
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2.2.3.3 DNA Isolation 
 
2.2.3.3.1 Plasmid DNA Isolation from Bacteria Culture 
The plasmid DNA isolation from bacterial culture was performed using GenEluteTM 
Plasmid Miniprep Kit (Sigma-Aldrich) according to the manufacturer’s 
recommendations.  
 
2.2.3.3.2 Vaccinia Virus DNA Isolation from Eukaryotic Cells 
 
2.2.3.3.2.1 Analytical Scale 
This method was used to isolate recombinant vaccinia virus DNA for further 
characterization. Infected CV-1 cells in a 6-well plate were scrapped off using a 
reversed pipette tip and centrifuged at 3000 rpm, RT for 3 minutes. The cell pellet 
was resuspended in 200 μl H2O. After addition of 200 μl Proteinase K buffer (2X) and 
4 μl of Proteinase K (10 mg/ml), the solution was mixed and incubated at 55 °C for 2 
hours. The DNA precipitation was performed as described in section 2.2.3.2.1. 
 
2.2.3.3.2.2 Preparative Scale 
Vaccinia virus DNA from infected BHK-21 cells was isolated in large scale for in vitro 
transcription (2.2.4.3). Infected BHK-21 cells from 8 cell culture dishes (15 cm 
diameter) were removed using a cell lifter and centrifuged at 3000 rpm, 4 °C for 5 
minutes. Supernatant was removed and cell pellet was resuspended in 4 ml ice cold 
Buffer A (1X). Cell suspension was aliquoted into MagNaLyser Green Beads tubes 
and homogenized at 5000 rpm for 20 sec with MagNaLyser (Roche). After 
homogenization, tubes were centrifuged (3000 rpm, 3min, 4 °C) and supernatant 
was pipetted into fresh reaction tubes (1ml/tube). After addition of 100 μl Trypsin 
solution to each tube, the cell lysate was incubated at 37 °C for 30 min. During the 
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incubation, 18 g of saccharose was dissolved in 50 ml H2O. 25 ml of the saccharose 
was transferred into a 50 ml canonical tube and gently overlaid with the trypsin-
digested cell lysate. Following centrifugation at 13000 rpm, 4 °C for 80 minutes, the 
supernatant was discarded and the virus pellet was resuspended in 700 μl Buffer A 
(1X). After addition of 80 μl DNase buffer (10X) and 8 μl RQ1 DNase (RNase-free), 
the virus suspension was incubated at 37 °C for 30 min. The DNase was inactivated 
by incubation at 65 °C for 20 min with additional 40 μl EDTA (10 mM). Virus 
suspension was divided into 4 aliquots (200 μl each).To each of the aliquots 200 μl 
Proteinase K Buffer (2X) and 4 μl Proteinase K was added and incubated at 55 °C 
for 2 hours. The DNA precipitation was performed as described in section 2.2.3.2.1. 
 
2.2.3.4 DNA Analysis 
 
2.2.3.4.1 DNA Agarose Gel Electrophoresis 
Agarose gel electrophoresis of DNA was used to analyze and isolate DNA. 1% 
agarose was prepared by mixing the agarose powder with Tris-acetate-EDTA buffer 
(TAE 1X) and boiled. Samples were mixed with DNA loading buffer in 4:1 ratio and 
transferred into the wells of the gel. GeneRuler 1 Kb Plus (Thermo Scientific) was 
used as a molecular marker. The electrophoresis was performed in ethidium 
bromide-stained 1X TAE buffer at 100 V for 45 minutes. After the electrophoresis, 
DNA bands were visualized with a UV table and documented using a camera.  
 
2.2.3.4.2 Sequencing 
Plasmid DNA or DNA purified after PCR (2.2.3.2.2) was mixed with appropriate 
sequencing primer and sent to Seqlab-Microsynth (Lindau, Germany) for 
sequencing. pGEM-T based plasmids were sequenced using M13 and M13r primers 
(2.1.12.2). The obtained results were analyzed using BioEdit software version 7.2.5.  
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2.2.3.5 Plasmid Generation 
cDNA obtained after reverse transcription of serotype II FIPV strain 79-1146 RNA 
(2.2.4.2) was used as a template for generation of plasmids. pGPT-1-Δ7ab plasmid 
contains sequence corresponding to nt 27651 to 29355 of the type II FIPV strain 79-
1146 genome, where 7ab genes (nt 28152 to 29082) are substituted with E. coli 
guanosine-phosphoribosyltransferase gene (gpt). To construct pGPT-1-Δ7ab, pGPT-
1 plasmid was used (Hertzig et al. 2004). In the first cloning step, sequence 
corresponding to nucleotides (nt) 27651 to 28151 of the type II FIPV strain 79-1146 
genome was amplified with PCR (primer pair 79-27650-F-XhoI and 79-28130-R-
EcoRI) (2.2.3.1.1), purified (2.2.3.2.2) and cloned into pGEM-T vector (Promega) 
(2.2.3.1.5). The generated plasmid and plasmid pGPT-1 were both treated with 
EcoRI and XhoI restriction enzymes (2.2.3.1.3). pGPT-1 vector was additionally 
dephosphorylated (2.2.3.1.4). Treated samples were resolved on an agarose gel 
(2.2.3.4.1), purified (2.2.3.2.3) and the type II FIPV strain 79-1146 sequence was 
ligated downstream of the gpt gene in the pGPT vector (2.2.3.1.5). In the second 
cloning step, obtained plasmid was used to incorporate the FIPV sequence 
(corresponding to nt 29083 to 29355 of type II FIPV strain 79-1146) upstream of the 
gpt gene in a similar way (primer pair 79-29085-F-SacII and 79-29355-R-SacI). In 
this step, SacII and SacI restriction enzymes were used. The resulting plasmid 
(pGPT-1-Δ7ab) was used for the generation of vrFIPV-GPT-Δ7ab (2.2.6.1).  
Plasmids pDF1 – pDF9 are based on the pGEM-T vector (Promega). Plasmid pDF1 
contains sequence corresponding to nt 27651 to 29355 of the type II FIPV strain 79-
1146 genome, where nt 28663 to 28665 were changed from AAT to TCA to replace 
asparagine with serine at aa position 68 in 7b protein. To generate this plasmid, 
sequence corresponding to nt 27651 to 29355 of the type II FIPV strain 79-1146 
genome was amplified with PCR and cloned into pGEM-T vector (primer pair 79-
27650-F-XhoI and 79-29355-R-SacI). The substitution of nt 28663 to 28665 from 
AAT to TCA was achieved with QuickChange PCR (primers 79-28653-F-QC-N68S 
and 79-28653-R-QC-N68S) (2.2.3.1.2). 
Plasmid pDF2 contains sequence corresponding to nt 27651 to 29355 of type II FIPV 
strain 79-1146, where additional flag tag sequence upstream of 7b gene (nt 28465) 
was inserted. To generate this plasmid, two sequences were amplified with PCR and 
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cloned into pGEM-T vector. Insert I corresponds to nt 27651 to 28464 (primer pair 
79-27650-F-XhoI and 79-28462-R-BsmBI) and insert II to 28465 to 29355 (primer 
pair 79-28462-F-BsmBI and 79-29355-R-SacI) of type II FIPV strain 79-1146. Both 
plasmids were then digested with BsmBI and NotI enzymes and resolved on an 
agarose gel. Following purification of DNA fragments from the gel, insert II was 
ligated into pGEM-T containing insert I. Plasmids pDF3 and pDF4 were generated 
with a similar approach. Plasmid pDF3 contains sequence corresponding to nt 27651 
to 29355 of type II FIPV strain 79-1146, where additional flag tag sequence was 
introduced downstream of nt 28512 of 7b gene. Nucleotide sequences 27651 to 
28512 (primer pair 79-27650-F-XhoI and 79-28485-R) and 28513 to 29355 (primer 
pair 79-28534-Fand 79-29355-R-SacI) were amplified by PCR for this purpose. 
Plasmid pDF4 contains nt 27651 to 29355 of type II FIPV strain 79-1146, with an 
additional flag tag sequence inserted downstream of 7b gene (nt 29079). Sequences 
corresponding to nt 27651 to 29079 (primer pair 79-27650-F-XhoI and 79-29049-R-
7bF) and nt 29080 to 29355 (primer pair 79-29082-F-7bF and 79-29355-R-SacI) of 
type II FIPV strain 79-1146 were amplified with PCR to construct this plasmid.  
Plasmids pDF5 – pDF9 were generated by performing QuickChange PCR on 
plasmid pDF3. The sequence of plasmid pDF5 is identical with pDF3, but in pDF5 nt 
28663 to 28665 were changed from AAT to TCA to replace asparagine with serine at 
aa position 68 in 7b protein. Primers 79-28653-F-QC-N68S and 79-28653-R-QC-
N68S were used for the QuickChange PCR. Plasmid pDF6 sequence is identical 
with pDF3, but in pDF6 leucine, corresponding to aa position 206 of 7b protein, was 
substituted with valine. This was achieved by altering nt 29077 to 29079 from TTA to 
GTT using 79-29077-F-KTEV and 79-29077-R-KTEV primers in QuickChange PCR. 
The sequence of pDF7 is identical with pDF3, but in pDF7 nucleotides corresponding 
to aa position 206 of 7b protein (29077 to 29079) are deleted. Primers 79-29077-F-
KTE and 79-29077-R-KTE were used for this purpose. Plasmid pDF8 sequence is 
identical with that of pDF3, but in pDF8 nt 29071 to 29073 were altered from ACT to 
GAT to substitute threonine with aspartic acid at position corresponding to aa 204 in 
7b protein. To achieve that, primers 79-29071-F-KDEL and 79-29071-R-KDEL were 
used. The sequence of pDF9 is identical with pDF3, but in pDF9 nt 29068 to 29079 
were replaced with GCAGCTGCTGCA to exchange KTEL with AAAA at position 
corresponding to aa 203-206 of 7b protein. Two rounds of QuickChange PCR were 
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needed to obtain pDF9. First, with primers 79-29068-F-AAEL and 79-29068-R-AAEL 
and second, on the obtained plasmid, with primers 79-29074-F-AAAA and 79-29074-
R-AAAA. Generated plasmids pDF1 – pDF9 were used to generate gpt negative 
recombinant vaccinia viruses (2.2.6.1.3).  
 
2.2.4 Molecular Techniques - RNA 
 
2.2.4.1 RNA Isolation from Eukaryotic Cells 
FIPV-infected FCWF-4 cells were harvested and centrifuged at 1400 rpm, 4 °C for 4 
min. Total RNA was isolated from the cell pellet using peqGOLD Total RNA Kit 
(PEQLAB) according to manufacturer’s recommendations. Isolated RNA was stored 
at -80 °C. 
 
2.2.4.2 Reverse Transcription 
RNA was transcribed into DNA using the Expand Reverse Transcriptase Kit (Roche). 
The following protocol was applied: 
 
Reagent Amount [μl] Reaction conditions  
1 μg isolated RNA 1-3   
Reverse primer (50 mM) 0.5   
ddH2O To 10.5 Denaturation 65 °C, 10 min 
  Cool on ice 4 °C 
5X Expand Reverse 
Transcriptase buffer 
4 
  
DTT (100 mM) 2   
dNTP mix 2   
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RNaseOUT 0.5   
Exapnd Reverse 
Transcriptase 50 U/μl 
1 Elongation 43 °C, 60 min 
Total volume 20 Cool on ice 4 °C 
Table 8. Reverse transcription standard protocol. 
 
Obtained cDNA was then used as a template for PCR (2.2.3.1.1).  
 
2.2.4.3 In vitro Transcription 
For the in vitro transcription (IVT), RiboMaxTM Large Scale RNA Production Systems 
kit (Promega) was used. Recombinant vaccinia virus DNA isolated in preparative 
scale (2.2.3.3.2.2) was digested with ClaI restriction enzyme for 3 hours at 37 °C and 
purified with Phenol/Chloroform procedure (2.2.3.2.1). Digested DNA was then used 
for the in vitro transcription:  
10 μl T7 Transcription 5X buffer 
5 μl RNA cap analog 
0.7 μl rGTP (100 mM) 
3.75 μl rATP, rCTP, rUTP (100 mM) 
5 μl  T7 enzyme mix 
1 μl RNaseOUT 
17 μl DNA after ClaI digestion 
The mixture was incubated at 30 °C for 2 h. After incubation, 2 μl of RQ1 DNase 
were added and the reaction tube incubated at 37 °C for 30 min. Following addition 
of 26 μl Lithium Chloride Precipitation Solution (Ambion), the RNA was precipitated 
at -20 °C for 30 minutes. Precipitated RNA was then centrifuged at 13000 rpm, 4 °C 
for 25 minutes, washed with 200 µl 70% ethanol and centrifuged again for 4 minutes. 
RNA pellet was resolved in 24 μl of RNA Storage Solution (Ambion). 2 μl RNA was 
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used for RNA electrophoresis (2.2.4.4.1) and the rest was electroporated into BHK-
FIPV-N cells (2.2.1.6.2).  
 
2.2.4.4 RNA Analysis 
 
2.2.4.4.1 RNA Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to assess the quality of the in vitro 
transcribed-RNA (2.2.4.3). 0.63 g agarose was mixed with 45.5 ml MOPS buffer (1X) 
and boiled. After cooling down the gel solution to 50 °C, 4.5 ml of 37% formaldehyde 
(Carl Roth) was added. 2 μl in vitro transcribed-RNA was mixed with 5 μl RNA Gel 
Loading Dye (2X) and denatured at 65 °C for 10 min. After addition of 1 μl ethidium 
bromide (10mg/ml), the sample was loaded on a gel and resolved in 1X MOPS 
buffer at 90 V for 45 min. After electrophoresis, RNA bands were visualized with a 
UV table and documented using a camera. 
 
2.2.5 Molecular Techniques for Working with Proteins 
 
2.2.5.1 Cell Lysis 
Cells were lysed in order to release proteins for further analysis. To achieve that, 
medium was removed from the cell culture dish, cells were washed with PBS and 
overlaid with RIPA buffer (80 μl per well in a 24-well plate). After 5 min incubation on 
ice, the lysate was collected in a reaction tube and sonicated twice for 2 sec. 
Aliquots of the lysate were stored at -20 °C. 
 
2.2.5.2 Protein Deglycosylation 
Cell lysates were treated either with Endo H (NEB) or PNGase F (NEB) according to 
manufacturer’s recommendations to remove sugar rests from glycosylated proteins.  
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2.2.5.3 Protein Analysis 
 
2.2.5.3.1 Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
SDS-PAGE (Laemmli 1970) was used to resolve proteins on a polyacrylamide gel for 
further analysis with Western blot (2.2.5.3.3) or for N-terminal Edman Sequencing 
(2.2.5.3.2). Tris-Tricine buffer system was used for this purpose (Schagger & von 
Jagow 1987). It allows the separation of small proteins between 1 and 100 kDa. It is 
a double-phase gel system, where proteins are first concentrated in the 4% stacking 
gel and then resolved in 10 % resolving gel. The gel recipe is presented in Table 9. 
 
Reagent Resolving gel 
(10%) 
Stacking gel 
(4%) 
Acrylamide, bisacrylamid 
solution 40% (29:1) 
9.0 ml 1.4 ml 
Glycerin (87%) 2 ml - 
Jagow gel buffer 12.0 ml 3.5 ml 
ddH2O 12.9 ml 9.0 ml 
APS (10%) 175 μl 116 μl 
TEMED 15 μl 12 μl 
Table 9. SDS-PAGE gel recipe. Gels were cast in The Sturdier SDS-PAGE system (Hoefer Scientific 
Instruments).  
 
Cell lysate or cell culture supernatant was mixed with SDS-PAGE sample loading 
buffer (4X) in a 4:1 ratio. Additionally, β-mercaptoethanol was added (5% total 
sample volume) and the sample denatured at 95 °C for 5 min. After loading on the 
gel, the samples were concentrated in the stacking gel at 60 V. Once the samples 
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have entered the resolving gel, the voltage was increased to 80 V overnight. 
Afterwards, samples were transferred onto a membrane. 
 
2.2.5.3.2 Immunoprecipitation and N-terminal Edman Sequencing 
To determine the exact signalase cleavage site in 7b protein, immunoprecipitated 7b 
protein sample was subjected to N-terminal Edman sequencing. To achieve that, 
rFIPV-7b(1-206/N68S) infected CRFK cells (MOI = 1) from a 10 cm culture dish were 
lysed with 1 ml RIPA buffer (2.2.5.1). The lysate was pipetted into a reaction tube, 
incubated at 4 °C for 30 min on a rotary shaker and centrifuged at 13000 rpm, 4 °C 
for 30 min. Supernatant was incubated with 300 μl anti-7b mAb 14D8 for 1 hour at 4 
°C on the rotary shaker. 300 μl of Protein G-SepharoseTM 4 Fast Flow beads was 
centrifuged at 10000 rpm, 4 °C for 1 min. The supernatant was removed, the beads 
were washed with 500 μl RIPA buffer and centrifuged twice. Washed beads were 
added to the lysate-antibody mixture and incubated for 1h at 4 °C on a rotary shaker. 
Excess protein was removed from the sample by washing 3 times with RIPA buffer. 
Washed beads were denatured with sample loading buffer (4X) and resolved using 
SDS-PAGE (2.2.5.3.1). 
After electrophoresis, the gel was incubated for 5 min in PVDF cathode transfer 
buffer. The PVDF membrane was activated in methanol for 2 minutes. The gel and 
the activated PVDF membrane were prepared for the semi-dry transfer as described 
in Figure 7. The transfer was performed at 15 V for 60 min using semi-dry transfer 
system (Bio-Rad).  
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Figure 7. Schematic representation of a semi-dry transfer sandwich. Buffers, in which the 
respective components were equilibrated are listed on the right. 
Transferred proteins were visualized on a PVDF membrane using Ponceau S 
solution (Sigma-Aldrich) and destained with ddH2O. The band corresponding to non-
glycosylated 7b protein (24 kDa) was excised and subjected to N-terminal Edman 
sequencing (Protein Analytik, Giessen).  
2.2.5.3.3 Western Blotting 
Western blot was used to detect 7b protein expressed in FIPV-infected cells. To 
achieve that, cell lysate or cell culture supernatant from FIPV-infected CFRK cells 
(MOI = 0.1) was mixed with sample loading buffer (4X), denatured and resolved 
using SDS-PAGE procedure (2.2.5.3.1). Proteins were then transferred onto a 
nitrocellulose membrane. Samples in the polyacrylamide gel and Whatman filter 
paper were equilibrated in the Western blot transfer cathode buffer, whereas 
nitrocellulose membrane and another filter in Western blot transfer anode buffer. For 
the assembly of the transfer sandwich, first a filter from the anode buffer was placed 
in the transfer chamber, then membrane, gel and at the end the filter paper from the 
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cathode buffer. The transfer was performed at 15 V for 60 min using semi-dry 
transfer system (Bio-Rad). 
After transfer, the nitrocellulose membrane was blocked with 5% milk in PBST for 1 
hour at room temperature. Following blocking, the membrane was washed twice with 
PBST for 5 min at RT and incubated with primary antibody diluted in PBST for 1 hour 
at RT. In order to detect 7b protein, two antibodies were used. Either anti-7b mAb 
14D8 diluted 1:35, which recognizes the non-glycosylated form of 7b protein or anti-
Flag® M2 (Sigma-Aldrich) diluted 1:100000, which detects a flag tag. After incubation 
with the primary antibody, the membrane was washed three times with PBST and 
incubated with Goat anti-mouse IgG-PO (1:20000 dilution) for 1 hour at RT. 
Following washing three times with PBST, the membrane was incubated with 
Western Lightning Plus-ECL Enhanced Chemiluminescence Substrate (Perkin 
Elmer) for 2 min at RT. The chemiluminescent signal from bound antibodies was 
recorded on X-ray films (Advansta). 
 
2.2.6 Techniques for Working with Viruses 
 
2.2.6.1 Vaccinia Virus 
 
2.2.6.1.1 Selection 
To obtain recombinant vaccinia viruses, a gpt gene (guanine 
phosphoribosyltransferase) originating from E. coli was applied as a selection marker 
(Eriksson et al. 2008; Hertzig et al. 2004; Kerr & Smith 1991; Tekes et al. 2008; 
Tekes et al. 2010; Tekes et al. 2012). 
 
2.2.6.1.2 Positive Selection 
The previously generated recombinant vaccinia virus vrFIPV was used (Tekes et al. 
2012) for positive selection. This virus contains the type II FIPV strain 79-1146 full-
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length genome as a cDNA. To obtain vrFIPV-GPT-Δ7ab, CV-1 cells were infected 
with vrFIPV and transfected (2.2.1.6.1) with plasmid pGPT-1-Δ7ab (2.2.3.5). During 
vaccinia virus replication recombination takes place between homologous parts of 
the vaccinia virus and the plasmid. Thus, this event leads to the integration of gpt 
gene into the vaccinia virus genome and loss of a part of the FIPV genome. The site 
of the recombination is directed by FIPV sequences located downstream and 
upstream of the gpt gene in the plasmid.  
CV-1 cells were seeded on a 6-well plate. Next day, the medium was changed to 
positive selection medium (2.1.8.2). 4-6 hours after replacement of the medium, cells 
were infected with a virus stock obtained after the infection/transfection (2.2.1.6.1) 
and incubated in a cell culture incubator for 48 h. 24 h p.i. the medium was replaced 
with fresh positive selection medium. 48 h p.i. plaques were marked and picked in 
150 μl of medium. Infected cells harvested this way were first subjected to three 
cycles of freezing in liquid nitrogen and thawing in an ultrasonic bath, before they 
were used for infection of new CV-1 cells. After 3-4 rounds of positive selection, DNA 
of recombinant vaccinia virus was isolated (2.2.3.3.2.1) and analyzed with PCR 
(2.2.3.1.1). 
 
2.2.6.1.3 Negative Selection 
To generate recombinant vaccinia viruses that contain altered forms of FIPV 7b 
gene, vrFIPV-GPT-Δ7ab (2.2.6.1.2) was used for negative selection. CV-1 cells 
infected with this virus were transfected (2.2.1.6.1) with plasmids pDF1 – pDF9, 
respectively (2.2.3.5). Double homologous recombination leads to substitution of the 
gpt gene by FIPV sequence in the vaccinia virus genome.  
D980R cells were seeded on a 6-well plate and on the next day, the medium was 
changed to the negative selection medium (2.1.8.2). 4-6 h after replacement of the 
medium, the cells were infected with the recombinant vaccinia virus and incubated in 
cell culture incubator for 48 h. 48 h p.i. plaques were harvested in 150 μl medium. 
Following three steps of freezing in liquid nitrogen and thawing in an ultrasonic bath, 
10-15 µl of the sample was used for the next selection round. After 3-4 rounds, 
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recombinant vaccinia virus DNA was isolated (2.2.3.3.2.1) and analyzed with PCR 
(2.2.3.1.1). 
2.2.6.1.4 Vaccinia Virus Plaque Purification Assay 
To further purify a recombinant vaccinia virus, plaque purification assay was used. In 
this approach, recombinant vaccinia virus was used to infect CV-1 cells. 48 h p.i. 
plaques were harvested in 150 μl medium. After three rounds of freezing in liquid 
nitrogen and thawing in an ultrasonic bath, infected cells were used to infect fresh  
CV-1 cells. Following 3 rounds of plaque purification, recombinant vaccinia virus 
DNA was isolated (2.2.3.3.2.1) and the integrity of FIPV cDNA was analyzed with 
PCR (2.2.3.1.1). Oligonucleotides used for the PCR are listed in Table 2 (2.1.12.1). 
Vaccinia virus plaque purification assay was used for all recombinant vaccinia 
viruses before vaccinia virus DNA was isolated in preparative scale (2.2.3.3.2.2).  
 
2.2.6.2 FIPV and Recombinant FIPV 
 
2.2.6.2.1 Titration of FIPVs 
To estimate the titer of FIPVs, FCWF-4 cells were first seeded on a 24-well plate. 
Next day, 10X serial dilutions of the virus stock in FCS-free CCM34 medium were 
prepared. The medium was removed from the cells, cells were washed with FCS-
free medium and overlaid with 250 μl of the appropriate virus suspension. After 1 h 
incubation, 1 ml CCM34 media with 1% carboxymethyl cellulose (CMC) was added 
to the cells to prevent the spread of virions through the media. After 20 h incubation, 
the plaques were counted and the titer was estimated using following equation: 
𝑛 × 𝑓 × 4 = 𝑃𝐹𝑈/𝑚𝑙 
n is the number of plaques counted in one well and f is the dilution factor. The result 
is given in plaque forming units (PFU) per milliliter. 
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2.2.6.2.2 Growth Kinetics of FIPVs 
To analyze the growth kinetics of FIPVs, FCWF-4 cells were seeded on a 6-well 
plate and infected with a virus at an MOI of 0.01. The cell culture supernatant was 
harvested (6, 12, 18 and 24 hours post infection) and titrated (2.2.6.2.1).  
 
2.2.7 Generation of Recombinant Viruses 
 
2.2.7.1 Generation of Recombinant Vaccinia Viruses 
To generate recombinant vaccinia viruses, vrFIPV was used in positive selection 
(2.2.6.1.2) with plasmid pGPT-1-Δ7ab (2.2.3.5). The resulting vrFIPV-GPT-Δ7ab was 
first analyzed with PCR (2.2.3.1.1) and plaque purified (2.2.6.1.4). After confirming 
the FIPV cDNA integrity, vrFIPV-GPT-Δ7ab was used for negative selection 
(2.2.6.1.3) with plasmids pDF1 – pDF9, respectively. The obtained recombinant 
vaccinia viruses were plaque purified and characterized with PCR. DNA of generated 
viruses was isolated in preparative scale (2.2.3.3.2.2), digested with ClaI enzyme 
and used for in vitro transcription (2.2.4.3) to recover recombinant FIPVs (2.2.7.2.1).  
 
2.2.7.2 Generation of Recombinant FIPVs 
 
2.2.7.2.1 Recovery of Recombinant FIPVs 
To recover recombinant FIPVs, in vitro-transcribed RNA (2.2.4.3) was electroporated 
into BHK-FIPV-N cells that were co-cultured with FCWF-4 cells (2.2.1.6.2). After 2 
days incubation, the co-culture was harvested and centrifuged at 1500 rpm, 4 °C for 
4 min. 2 ml of the supernatant were used to infect fresh FCWF-4 cells on a 10 cm 
dish. The rest of the co-culture supernatant was stored at -80 °C. Infected FCWF-4 
cells were harvested and used for RNA isolation (2.2.4.1) and RT-PCR (2.2.4.2) to 
confirm the sequence of the recombinant virus. Supernatant was aliquoted, stored at 
-80 °C and used to determine the virus titer (2.2.6.2.1). Recombinant FIPVs (rFIPVs) 
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were used to infect cells for indirect immunofluorescence assay (2.2.1.5), 
immunoprecipitation and N-terminal Edman sequencing (2.2.5.3.2) and Western blot 
(2.2.5.3.3). 
 
2.2.7.2.2 Plasmids, Recombinant Vaccinia Viruses and 
Recombinant FIPVs 
(a) 
Name of the vaccinia clone used:  vrFIPV 
Name of the plasmid:   pGPT-1-Δ7ab 
Name of the generated vaccinia virus: vrFIPV-GPT-Δ7ab 
vrFIPV-GPT-Δ7ab contains type II FIPV strain 79-1146 cDNA, where 7ab gene was 
substituted with the gpt gene. This recombinant vaccinia virus was used to generate 
all below mentioned recombinant viruses.  
 
(b) 
Name of the plasmid:   pDF1 
Name of the generated vaccinia virus: vrFIPV-7b(1-206/N68S) 
Name of the generated rFIPV:  rFIPV-7b(1-206/N68S) 
In rFIPV-7b(1-206/N68S) nt 28663 to 28665 were changed from AAT to TCA which 
leads to substitution of asparagine with serine in 7b protein at aa position 68. 
 
(c) 
Name of the plasmid:   pDF2 
Name of the generated vaccinia virus: vrFIPV-flag-7b(1-206) 
Name of the generated rFIPV:  rFIPV-flag-7b(1-206) 
In rFIPV-flag-7b(1-206) an additional flag tag sequence preceding 7b gene 
(downstream of nt 28464) was inserted. 
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(d) 
Name of the plasmid:   pDF3 
Name of the generated vaccinia virus: vrFIPV-7b(1-17/flag/18-206) 
Name of the generated rFIPV:  rFIPV-7b(1-17/flag/18-206) 
rFIPV-7b(1-17/flag/18-206) contains an additional flag tag sequence introduced 
downstream of nt 28512, which corresponds to aa position 17 of 7b protein. 
 
(e) 
Name of the plasmid:   pDF4 
Name of the generated vaccinia virus: vrFIPV-7b(1-206)-flag 
Name of the generated rFIPV:  rFIPV-7b(1-206)-flag 
In rFIPV-7b(1-206)-flag an additional flag tag sequence was inserted downstream of 
nt 29079 that corresponds to the C-terminal end of 7b protein. 
 
(f) 
Name of the plasmid:   pDF5 
Name of the generated vaccinia virus: vrFIPV-7b(1-17/flag/18-206/N68S) 
Name of the generated rFIPV:  rFIPV-7b(1-17/flag/18-206/N68S) 
rFIPV-7b(1-17/flag/18-206/N68S) contains a flag tag sequence downstream of nt 
28512 that corresponds to aa 17 of 7b protein. Additionally, nt 28663 to 28665 were 
changed from AAT to TCA which leads to substitution of asparagine with serine in 7b 
protein at aa position 68. 
 
(g) 
Name of the plasmid:   pDF6 
Name of the generated vaccinia virus: vrFIPV-7b(1-17/flag/18-202/KTEV) 
Name of the generated rFIPV:  rFIPV-7b(1-17/flag/18-202/KTEV) 
In rFIPV-7b(1-17/flag/18-202/KTEV) an additional flag tag sequence was inserted 
downstream of nt 28512 that corresponds to aa 17 of 7b protein. Moreover, nt 29077 
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to 29079 were altered from TTA to GTT, substituting leucine with valine in 7b protein 
at aa position 206. 
(h) 
Name of the plasmid:   pDF7 
Name of the generated vaccinia virus: vrFIPV-7b(1-17/flag/18-202/KTE) 
Name of the generated rFIPV:  rFIPV-7b(1-17/flag/18-202/KTE) 
rFIPV-7b(1-17/flag/18-202/KTE) contains a flag tag sequence downstream of nt 
28512 that corresponds to aa 17 of 7b protein and a deletion of nt 29077 to 29079, 
resulting in removal of aa 206 in 7b protein 
 
(i) 
Name of the plasmid:   pDF8 
Name of the generated vaccinia virus: vrFIPV-7b(1-17/flag/18-202/KDEL) 
Name of the generated rFIPV:  rFIPV-7b(1-17/flag/18-202/KDEL) 
InrFIPV-7b(1-17/flag/18-202/KDEL) a flag tag was inserted downstream of nt 28512 
corresponding to aa 17 of 7b protein. Additionally, nt 29071 to 29073 were altered 
from ACT to GAT to substitute threonine with aspartic acid in 7b protein at aa 
position 204.  
 
(j) 
Name of the plasmid:   pDF9 
Name of the generated vaccinia virus: vrFIPV-7b(1-17/flag/18-202/AAAA) 
Name of the generated rFIPV:  rFIPV-7b(1-17/flag/18-202/AAAA) 
rFIPV-7b(1-17/flag/18-202/AAAA) contains a flag tag downstream of nt 28512 that 
corresponds to aa 17 of 7b protein. Furthermore, nt 29068 to 29079 were changed to 
GCAGCTGCTGCA to replace the C-terminal KTEL sequence (aa 203-206) of 7b 
protein with 4 alanine residues (AAAA). 
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3 Results 
 
3.1 Generation of Recombinant FIPV Expressing the Non-
glycosylated 7b Protein 
In order to study expression and localization of serotype II FIPV strain 79-1146 7b 
protein in infected feline cells, monoclonal antibodies (mAbs) against 7b protein were 
previously generated at the Institute of Virology, JLU, Giessen (Lemmermeyer et al. 
2016). Detailed characterization of the mAbs revealed that they recognized only the 
non-glycosylated precursor of 7b protein. Since 7b represents a glycoprotein (Fig. 8), 
certain aspects, like expression, subcellular localization or secretion of the authentic 
protein, could not be studied using these antibodies. To overcome this limitation, a 
recombinant FIPV expressing the non-glycosylated form of 7b protein was 
generated.  
 
Figure 8. Prediction of N-linked glycosylation site based on amino acid sequence of 7b protein. 
NetNGlyc 1.0 online analyzer predicted one N-glycosylation site at amino acid position 68 in 7b 
protein. 
 
Comparison of available 7b protein sequences revealed that some FCoV field 
isolates contain serine instead of asparagine at amino acid position 68 in 7b protein. 
To enable the detection of non-glycosylated 7b protein in FIPV-infected cells by the 
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mAbs, a recombinant virus that expresses 7b protein without the only glycosylation 
site was generated using vaccinia virus-based reverse genetic system (see below).  
3.1.2 Generation of Recombinant Vaccinia Virus vrFIPV-GPT-
Δ7ab
To allow the modification of 7b gene, recombinant vaccinia virus vrFIPV-GPT-Δ7ab 
was generated. For this purpose, a recombinant vaccinia virus containing the type II 
FIPV strain 79-1146 full-length genome as cDNA (vrFIPV) (Tekes et al. 2012) was 
used to infect CV-1 cells. Infected cells were then transfected with plasmid pGPT-1-
Δ7ab (2.2.3.5 and 2.2.1.6.1). During incubation, vaccinia virus-mediated homologous 
recombination takes place between the vaccinia virus- and the plasmid-DNA leading 
to the replacement of part of the FIPV sequence by the guanine 
phosphoribosyltransferase (gpt) gene that served as a selection marker. In order to 
investigate the proper integration of the gpt-gene into the vrFIPV genome after gpt 
positive selection (2.2.6.1.2) (Fig. 9A), vrFIPV-GPT-Δ7ab DNA was isolated from 
infected CV-1 cells (2.2.3.3.2.1). The recombination sites were amplified with PCR 
(2.2.3.1.1) (Fig. 9B and C). PCR fragment C was used as a control to show that the 
obtained recombinant vaccinia virus was not contaminated with the parental vrFIPV. 
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Figure 9. Generation and analysis of recombinant vaccinia virus vrFIPV-GPT-Δ7ab. (A) 
Schematic representation of the positive selection of vrFIPV-GPT-Δ7ab. (B) Positions of the PCR
fragments as well as applied primers are presented. (C) PCR analysis of vrFIPV-GPT-Δ7ab 
recombinant vaccinia virus DNA. PCR products were resolved in ethidium bromide-stained 1% 
agarose gel. The size of selected marker bands is shown on the right. I, PCR fragment I; II, PCR 
fragment II; C, PCR fragment C; M, DNA marker. 
After sequence analysis of the recombination sites, vrFIPV-GPT-Δ7ab was plaque 
purified (2.2.6.1.4). Furthermore, the entire FIPV genome was amplified by 12 PCR 
products to demonstrate its integrity (Fig. 10). The characterized vrFIPV-GPT-Δ7ab 
served as a starting material for negative selection to generate all viruses used in 
this thesis expressing altered forms of 7b protein (see below). 
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Figure 10. Amplification of the FIPV genome in recombinant vaccinia virus vrFIPV-GPT-Δ7ab.
(A) Schematic representation of the FIPV cDNA inserted into vrFIPV-GPT-Δ7ab genome. Positions of 
12 PCR fragments (1-12) are shown. Primer pairs used for the PCR products are listed in Table 2 
(2.1.12.1). (B) PCR products were resolved in ethidium bromide-stained 1% agarose gel. The size of 
selected marker bands is shown on the left. M, DNA marker. 
3.1.3 Generation of vrFIPV-7b(1-206/N68S) 
In order to introduce serine instead of asparagine at amino acid position 68 in 7b 
protein, CV-1 cells were infected with vrFIPV-GPT-Δ7ab and transfected with pDF1 
plasmid (2.2.3.5 and 2.2.1.6.1). During incubation, vaccinia virus-mediated 
homologous recombination takes place between the vaccinia virus- and the plasmid-
DNA that leads to the replacement of gpt gene by the desired FIPV sequence. After 
selection of gpt-negative recombinant vaccinia virus (2.2.6.1.3), viral DNA was 
isolated and analyzed with PCR (Fig. 11) (2.2.7.1). The integration of the altered 
FIPV sequence was confirmed by amplification and sequencing of the recombination 
sites (Fig. 11B and C). PCR fragment G was used as a control to show that the 
obtained recombinant vaccinia virus was not contaminated with the parental vrFIPV-
GPT-Δ7ab.
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Figure 11. Generation and analysis of recombinant vaccinia virus vrFIPV-7b(1-206/N68S). (A) 
Schematic representation of the negative selection ofvrFIPV-7b(1-206/N68S). (B) Positions of the 
PCR fragments, as well as applied primers are presented. (C) PCR analysis of vrFIPV-7b(1-
206/N68S) recombinant vaccinia virus DNA. PCR products were resolved in ethidium bromide-stained 
1% agarose gel. The size of selected marker band is shown on the left. I, PCR fragment I; II, PCR 
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fragment II; G, PCR fragment G; M, DNA marker. Asterisk indicates the substitution of asparagine 
with serine at amino acid position 68 (N68S) of 7b protein.
Following sequence analysis of the recombination sites, vrFIPV-7b(1-206/N68S) was 
plaque purified and the integrity of FIPV cDNA was analyzed with PCR (Fig.12), as 
described previously in Figure 10.  
Figure 12. Amplification of the FIPV genome in recombinant vaccinia virus vrFIPV-7b(1-
206/N68S) DNA.12 PCR products (1-12) containing the full-length FIPV cDNA were resolved in 
ethidium bromide-stained 1% agarose gel. The size of selected marker bands is shown on the left. M, 
DNA marker. 
3.1.4 Recovery of rFIPV-7b(1-206/N68S) 
For the recovery of rFIPV-7b(1-206/N68S), the DNA of the recombinant vaccinia 
virusvrFIPV-7b(1-206/N68S) was isolated in preparative scale (2.2.3.3.2.2) and 
analyzed with agarose gel electrophoresis (Fig. 13A).  
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Figure 13. Analysis of the vrFIPV-7b(1-206/N68S) DNA and the transcribed RNA. (A) 2 µl of 
vrFIPV-7b(1-206/N68S) DNA was loaded on 1% agarose gel to control its quality. The size of 
selected marker band is shown on the left. (B) 2 µl of the in vitro-transcribed RNA (rFIPV-7b(1-
206/N68S)) was resolved on 1.3% agarose gel to control its quality. 
 
The DNA was then used as a template for in vitro transcription (2.2.4.3). The quality 
of the obtained RNA was also assessed using gel electrophoresis (Fig. 13B). Next, 
rFIPV-7b(1-206/N68S) RNA was electroporated (EP) (2.2.1.6.2) into BHK-FIPV-N 
cells. In these cells, the electroporated RNA initiates the viral replication cycle that 
leads to the release of infectious virions. Expression of FIPV nucleocapsid protein in 
BHK-FIPV-N cells facilitates the replication of the recombinant FIPVs. Since BHK-
FIPV-N cells do not express receptors for FIPV, these cells cannot be infected with 
newly released virions. Therefore, the BHK-FIPV-N cells were co-cultured with 
susceptible feline cells (FCWF-4) (2.2.7.2.1). 48 hours post EP, the cell culture 
supernatant was harvested and centrifuged to remove cell debris. Subsequently, the 
supernatant was used to infect fresh FCWF-4 cells. After 24-48 h incubation, the 
supernatant containing rFIPV-7b(1-206/N68S) was harvested, stored at -80 °C and 
used for further experiments. The infected cells were used for PCR analyses. After 
sequencing of the PCR-products, asparagine to serine exchange at aa position 68 in 
7b could be verified (Fig. 14A). The supernatant was used to determine the growth 
kinetics of rFIPV-7b(1-206/N68S). The analysis revealed that the growth kinetics of 
rFIPV-7b(1-206/N68S) were identical to those of the type II FIPV strain 79-1146 (Fig. 
14B). 
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Figure 14. Characterization of rFIPV-7b(1-206/N68S). (A) Sequence analyses of type II FIPV strain 
79-1146 and rFIPV-7b(1-206/N68S). Asterisk indicates the exchange of AAT (asparagine) to TCA 
(serine) at position corresponding to amino acid 68 in 7b protein.(B) Growth kinetics of rFIPV-7b(1-
206/N68S) compared to type II FIPV strain 79-1146; p.i., post infection.  
3.1.5 Characterization of the Non-glycosylated Form of 7b 
Protein Using rFIPV-7b(1-206/N68S) 
rFIPV-7b(1-206/N68S) was used to determine the subcellular localization of the non-
glycosylated form of 7b protein (Fig. 15A) in infected CRFK cells. Following infection, 
cells and cell culture supernatant were harvested 16 hours post infection, before 
cytopathic effect (CPE) developed. This time point was chosen to avoid detection of 
7b protein in the supernatant caused by the lysis of infected cells. The samples were 
analyzed with Western Blot using anti-7b mAb 14D8 (2.2.5.3.3) (Fig. 15B). The 
experiment showed that 7b protein was present only in the cell lysate but not in the 
cell culture supernatant. Accordingly, the non-glycosylated 7b protein was probably 
not secreted. To determine the subcellular localization of the non-glycosylated 7b 
protein, rFIPV-7b(1-206/N68S)-infected CRFK cells were analyzed with indirect 
immunofluorescence assay using confocal microscopy with anti-7b mAb (2.2.1.5). 
The experiment demonstrated that 7b protein co-localized exclusively with the Golgi 
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apparatus (Fig.15C). These results contradict observations by Vennema et al. 
(1992); they described 7b protein as an endoplasmic reticulum (ER)-resident protein 
that is secreted from the cell. 
Figure 15. 7b protein detection in FIPV-infected cells using anti-7b monoclonal antibody 14D8 
(α-7b mAb). (A) Schematic representation of 7b protein encoded by rFIPV-7b(1-206/N68S). Asterisk 
indicates the substitution of asparagine with serine at amino acid position 68 (N68S). SP, signal 
peptide; numbers indicate the amino acid positions of 7b protein. (B) rFIPV-7b(1-206/N68S) infected 
CRFK cells (MOI = 0.1) were harvested 16 h post infection. Cell lysate (c) and cell culture supernatant 
(s) were resolved in a 10% polyacrylamide gel under reducing conditions and analyzed by Western 
Blot with anti-7b mAb 14D8. (C) rFIPV-7b(1-206/N68S)-infected (MOI = 1) and non-infected CRFK 
cells were fixed 16 h p.i. and stained for immunofluorescence analysis. 7b protein was visualized 
using anti-7b mAb 14D8. Immunofluorescence staining of cell structures: endoplasmic reticulum (ER) 
(left panel) and Golgi apparatus (right panel) is demonstrated. Cell nuclei were stained blue using 
DAPI. Immunofluorescence staining was visualized with confocal laser scanning microscope (adapted
from Florek et al., 2017).
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3.2 FIPVs with Flag-tagged Forms of 7b Protein 
To investigate whether the observed differences with the results of Vennema and 
colleagues (1992)are related to the absence of glycosylation in 7b protein, a different 
approach was taken to study the mature, glycosylated form of 7b protein. For this, a 
set of recombinant FIPVs expressing flag-tagged forms of 7b protein was 
constructed using the above described vaccinia virus-based reverse genetic system. 
 
3.2.2 Generation of rFIPV-flag-7b(1-206) 
In order to obtain recombinant vaccinia virus vrFIPV-flag-7b(1-206) where flag tag is 
fused to the N-terminus of 7b, CV-1 cells were infected with vrFIPV-GPT-Δ7ab and 
transfected with pDF2 plasmid (2.2.7.1) as shown in Figure 11. After selection of gpt-
negative recombinant vaccinia viruses, viral DNA was isolated and analyzed with 
PCR (Fig. 16). 
After sequence analysis of the recombination sites, vrFIPV-flag-7b(1-206) was 
plaque purified and the integrity of the viral genome was assessed with PCR as 
described in Figure 10.  
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Figure 16. Analysis of recombinant vaccinia virus vrFIPV-flag-7b(1-206). (A) Positions of the 
PCR fragments, as well as applied primers are presented. Black box represents the flag tag in 7b 
gene. (B) PCR analysis of vrFIPV-flag-7b(1-206) recombinant vaccinia virus DNA. PCR products 
were resolved in ethidium bromide-stained 1% agarose gel. The size of selected marker band is 
shown on the right. I, PCR fragment I; II, PCR fragment II; G, PCR fragment G; M, DNA marker. 
For the recovery of rFIPV-flag-7b(1-206), the DNA of the recombinant vaccinia virus 
vrFIPV-flag-7b(1-206) was isolated in preparative scale (2.2.3.3.2.2) and analyzed 
with agarose gel electrophoresis as shown in Figure 13. The DNA was then used as 
a template for in vitro transcription (2.2.4.3). In the next step, rFIPV-flag-7b(1-206) 
RNA was electroporated (EP) (2.2.1.6.2) into BHK-FIPV-N cells and co-cultured with 
FCWF-4 cells (2.2.7.2.1). 48 hours post EP, the cell culture supernatant was 
harvested and centrifuged to remove cell debris. Subsequently, the supernatant was 
used to infect fresh FCWF-4 cells. After 24-48 h incubation, the supernatant 
containing rFIPV-flag-7b(1-206) was harvested, stored at -80 °C and used for further 
experiments. The infected cells were used for PCR analyses. After sequencing of the 
PCR-products, insertion of the flag tag at the N-terminus of 7b was verified 
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(Fig.17A). Growth kinetics of rFIPV-flag-7b(1-206) were identical to those of the type 
II FIPV strain 79-1146 (Fig. 17B). 
Figure 17. Characterization of rFIPV-flag-7b(1-206). (A) Sequence analyses of type II FIPV strain 
79-1146 and rFIPV-flag-7b(1-206). Flag tag sequence preceding 7b gene is shown. M, methionine. 
(B) Growth kinetics of rFIPV-flag-7b(1-206) compared to type II FIPV strain 79-1146;p.i., post 
infection.
3.2.3 Detection of 7b Protein after Infection with rFIPV-flag-
7b(1-206). 
To investigate the expression and localization of the mature, glycosylated form of 7b 
protein in FIPV-infected cells, rFIPV-flag-7b(1-206) was used (Fig. 18A). CRFK cells 
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were infected with this virus and before CPE developed, cells and cell culture 
supernatant were harvested and analyzed with Western Blot (Fig. 18B).  
Figure 18. Western blot analysis of N-terminal flag-tagged 7b protein in rFIPV-flag-7b(1-206)-
infected CRFK cells. (A) Schematic representation of 7b protein encoded by rFIPV-flag-7b(1-206). 
Black box represents the flag tag at the N-terminus of 7b protein. SP, predicted signal peptide; 
numbers indicate the amino acid positions in 7b protein. (B) CRFK cells infected with rFIPV-flag-7b(1-
206) were harvested 16 h post infection. Cell lysate (c) and cell culture supernatant (s) were analyzed 
by Western Blot with anti-Flag® M2 (α-flag mAb) or anti-7b mAb 14D8 (α-7b mAb). 
Using anti-flag mAb, 7b could not be detected in the cell lysate as well as in the cell 
culture supernatant. Only the non-glycosylated form of 7b protein (ca. 24 kDa) was 
detected in the cell lysate with anti-7b mAb 14D8. This result suggests that the flag 
tag together with the predicted N-terminal signal peptide were cleaved off by the 
signalase.  
3.2.4 Signalase Cleavage Site in 7b Protein 
Since the predicted signal peptide of 7b protein is obviously removed during 
synthesis into the ER, the flag tag had to be introduced at a different position. To 
enable the introduction of the flag tag downstream of the signal peptide, the exact 
cleavage site of the signalase was determined. 7b protein sequence was subjected 
to SignalP 4.1 online analyzer (Petersen et al. 2011) that predicted two potential 
signalase cleavage site between amino acids 17-18 and 19-20 (13-GIKA↓TA↓VQND-
24) (Fig. 19).  
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Figure 19. Signal peptide prediction for FCoV 7b protein. Two possible signalase cleavage sites in 
7b protein are indicated by arrows. C-score demonstrates the score for signal peptide cleavage sites; 
S-score distinguishes amino acid positions within signal peptides from positions in the mature protein; 
Y-score is a combination of the C-score and the slope of the S-score and serves for better cleavage 
site prediction. 
 
To experimentally determine which of the two predicted cleavage sites is used by the 
signalase, CRFK cells were infected with rFIPV-7b(1-206/N68S). Cells were 
harvested 24 hours post infection, lysed and 7b protein was immunoprecipitated with 
anti-7b mAb 14D8. The sample was resolved with SDS-PAGE and transferred to a 
PVDF membrane. Proteins on the membrane were visualized with Ponceau staining 
(2.2.5.3.2). The band corresponding to the non-glycosylated form of 7b protein was 
excised from the membrane and subjected to N-terminal Edman sequencing. It could 
be shown that the signalase cleavage occurred between amino acids 17 and 18. The 
result of the N-terminal protein sequencing is demonstrated in Table 10. 
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N-terminal sequence 
determined by Edman 
sequencing 
Corresponding 7b 
protein sequence 
1    T 18    T 
2    A 19    A 
3    V 20    V 
4    Q 21    Q 
5    N 22    N 
6    D 23    D 
7    L 24    L 
 25    H 
 26    E 
 27    H 
Table 10. N-terminal Edman sequencing of 7b protein. Numbers indicate the amino acid positions 
in 7b protein. 
 
3.2.5 Generation of rFIPV-7b(1-17/flag/18-206) and rFIPV-7b(1-
17/flag/18-206/N68S). 
To detect 7b protein in infected cells with anti-flag mAb, a flag tag was introduced 
downstream of the determined signalase cleavage site (amino acid 17) in 7b using 
vaccinia virus-based reverse genetic system (rFIPV-7b(1-17/flag/18-206)). Moreover, 
a recombinant virus identical to rFIPV-7b(1-17/flag/18-206), but in addition with a 
mutation leading to substitution of asparagine with serine at amino acid position 68 
(N68S) of 7b was generated (rFIPV-7b(1-17/flag/18-206/N68S)). This mutation was 
included to abolish N-linked glycosylation in flag-tagged 7b protein enabling the 
direct comparison of expression and localization of the glycosylated versus non-
glycosylated forms of 7b protein in FIPV-infected cells. 
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For this purpose, recombinant vaccinia viruses vrFIPV-7b(1-17/flag/18-206) and 
vrFIPV-7b(1-17/flag/18-206/N68S) were generated. CV-1 cells were infected with 
vrFIPV-GPT-Δ7ab and transfected with pDF3 and pDF5 plasmids, respectively 
similar as shown in Figure 11. After selection of gpt-negative recombinant vaccinia 
viruses, viral DNA was isolated and analyzed with PCR (Fig. 20). After sequence 
analysis of the recombination sites, vrFIPV-7b(1-17/flag/18-206) and vrFIPV-7b(1-
17/flag/18-206/N68S) were plaque purified and the integrity of the viral genome was 
assessed with PCR as described in Figure 10. 
Figure 20. Analysis of recombinant vaccinia viruses vrFIPV-7b(1-17/flag/18-206) and vrFIPV-
7b(1-17/flag/18-206/N68S). (A) Positions of the PCR fragments, as well as applied primers are 
presented. (B) PCR analysis of vrFIPV-7b(1-17/flag/18-206) and vrFIPV-7b(1-17/flag/18-206/N68S) 
recombinant vaccinia virus DNA. PCR products were resolved in ethidium bromide-stained 1% 
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agarose gel. The size of selected marker bands is shown on the left. I, PCR fragment I; II, PCR 
fragment II; G, PCR fragment G; M, DNA marker. 
 
For the recovery of vrFIPV-7b(1-17/flag/18-206) and vrFIPV-7b(1-17/flag/18-
206/N68S), the DNA of the recombinant vaccinia viruses vrFIPV-7b(1-17/flag/18-
206) and rFIPV-7b(1-17/flag/18-206/N68S) was isolated in preparative scale 
(2.2.3.3.2.2) and analyzed with agarose gel electrophoresis as shown in Figure 13, 
respectively. The DNA was used as a template for in vitro transcription (2.2.4.3). In 
the next step, rFIPV-7b(1-17/flag/18-206) and rFIPV-7b(1-17/flag/18-206/N68S) RNA 
was electroporated (EP) (2.2.1.6.2) into BHK-FIPV-N cells and co-cultured with 
FCWF-4 cells, respectively (2.2.7.2.1). 48 hours post EP, the cell culture supernatant 
was harvested and centrifuged to remove cell debris. Subsequently, the supernatant 
was used to infect fresh FCWF-4 cells. After 24-48 h incubation, the supernatant 
containing recombinant FIPVs was harvested, stored at -80 °C and used for further 
experiments. The infected cells were used for PCR analyses. After sequencing of the 
PCR-products, insertion of the flag tag downstream of the signalase cleavage site of 
7b could be verified for both rFIPV-7b(1-17/flag/18-206) and rFIPV-7b(1-17/flag/18-
206/N68S) (Fig. 21A). Moreover, rFIPV-7b(1-17/flag/18-206/N68S) contained an 
additional mutation corresponding to N68S alteration (Fig. 21B). Growth kinetics of 
rFIPV-7b(1-17/flag/18-206) and rFIPV-7b(1-17/flag/18-206/N68S) were identical to 
those of the type II FIPV strain 79-1146(Fig. 21C). 
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Figure 21. Characterization of rFIPV-flag-7b(1-206) and rFIPV-flag-7b(1-206/N68S). (A) Sequence 
analyses of type II FIPV strain 79-1146, rFIPV-7b(1-17/flag/18-206) and rFIPV-7b(1-17/flag/18-
206/N68S). Flag tag sequence introduced downstream of the signalase cleavage site in 7b protein is 
demonstrated. (B) Nucleotide sequence AAT (asparagine) was substituted with TCA (serine) in 
rFIPV-7b(1-17/flag/18-206/N68S) (asterisk). (C) Growth kinetics of rFIPV-7b(1-17/flag/18-206) and 
rFIPV-7b(1-17/flag/18-206/N68S) compared to type II FIPV strain 79-1146;p.i., post infection. 
3.2.6 Characterization of 7b Protein in rFIPV-7b(1-17/flag/18-
206)- and rFIPV-7b(1-17/flag/18-206/N68S)-infected Cells. 
To analyze the subcellular localization of 7b protein in infected cells, CRFK cells 
were infected with rFIPV-7b(1-17/flag/18-206) and rFIPV-7b(1-17/flag/18-206/N68S),
respectively. 16 h post infection, before CPE developed, cells and cell culture 
supernatant were harvested and analyzed by Western Blot with anti-Flag® M2 (α-flag 
mAb) (Fig. 22B).  
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Figure 22. Detection of 7b protein in FIPV-infected cells. (A) Schematic representation of 7b 
protein encoded by rFIPV-7b(1-17/flag/18-206) and rFIPV-7b(1-17/flag/18-206/N68S). Black boxes 
represent the position of a flag tag in 7b protein. Asparagine to serine mutation at amino acid position 
68 (N68S) is indicated by an asterisk. SP, signal peptide; numbers indicate the amino acid positions 
in 7b protein. Arrow: signalase cleavage site. (B) CRFK cells were infected with rFIPV-7b(1-
17/flag/18-206) and rFIPV-7b(1-17/flag/18-206/N68S) at an MOI of 0.1, respectively. Cells and cell 
culture supernatants were harvested at 16 h p.i. Cell lysates (c) and cell culture supernatants (s) were 
separated by SDS-PAGE (10 %) under reducing conditions and analyzed by Western Blot using anti-
flag mAb (α-flag mAb). (C) CRFK cells were infected with rFIPV-7b(1-17/flag/18-206) and rFIPV-7b(1-
17/flag/18-206/N68S) at an MOI of 1 or mock infected, respectively. Cells were fixed 16 h p.i. and 
analyzed by confocal laser scanning microscopy. Immunofluorescence staining of 7b protein was 
performed with anti-flag mAb (α-flag mAb). Immunofluorescence staining of the endoplasmic 
reticulum (ER) (left panel) and the Golgi complex (right panel) is shown. Cell nuclei were stained blue 
with DAPI (adapted from Florek et al., 2017).
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These experiments showed that 7b protein was detected only in both cell lysates but 
not in cell culture supernatants. Accordingly, independent of its glycosylation state 
the 7b protein is not secreted but retained in FIPV-infected cells. To determine the 
subcellular localization of the glycosylated versus non-glycosylated forms of 7b 
protein, confocal microscopy analysis was performed (Fig. 22C). CRFK cells were 
infected with rFIPV-7b(1-17/flag/18-206) and rFIPV-7b(1-17/flag/18-206/N68S), 
respectively and fixed 16 h post infection. The immunofluorescence analysis with 
anti-Flag® M2 (α-flag mAb) revealed that both the glycosylated and the non-
glycosylated forms of 7b protein co-localized exclusively with the Golgi apparatus. 
The results of the Western blot and confocal microscopy are identical with the 
outcome of the experiments performed with rFIPV-7b(1-206/N68S)-infected cells 
(Fig. 15) indicating that flag-tagged 7b protein at amino acid position 17 is well suited 
for characterization of the protein in FIPV-infected cells.  
3.3 Subcellular Localization of 7b Protein 
To determine the localization of 7b protein more precisely, cell lysates from rFIPV-
7b(1-17/flag/18-206)-infected CRFK cells were subjected to either Endoglycosidase 
H (Endo H) or PNGase F glycosidase treatment and analyzed with Western Blot 
using anti-Flag® M2 antibody (α-flag mAb) (Fig. 23).  
Figure 23. Glycosidase treatment of 7b protein. (A) Schematic representation of 7b protein 
encoded by rFIPV-7b(1-17/flag/18-206) and rFIPV-7b(1-17/flag/18-206/N68S). Black boxes represent 
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the position of a flag tag in 7b protein. Asparagine to serine mutation at amino acid position 68 (N68S) 
is indicated by an asterisk. SP, signal peptide; numbers indicate the amino acid positions in 7b 
protein. The arrow represents the signalase cleavage site. (B) CRFK cells were infected with rFIPV-
flag-7b(18-206) at an MOI of 0.1. rFIPV-flag-7b(18-206)-N68S-infected cells were used as a control. 
Cells were harvested at 16 h p.i. and cell lysates subjected to glycosidase (PNGase F or Endo H) 
treatment (+) or left untreated (-). Subsequently, cell lysates were separated by SDS-PAGE (10%) 
under reducing conditions and analyzed by Western blot using anti-Flag
®
 M2 antibody (α-flag mAb) 
(adapted from Florek et al., 2017). 
 
Since different steps of N-glycosylation occur in certain cellular compartments, 
treatment with various glycosidases allows to determine the intracellular localization 
of glycoproteins, like 7bin FIPV-infected cells. While PNGase F enzyme completely 
removes asparagine-linked sugars from glycoproteins, Endo H cleaves off high 
mannose oligosaccharide side chains, but not the complex glycan structures. 
PNGase F treatment of 7b protein originating from rFIPV-7b(1-17/flag/18-206)-
infected CRFK cells led to co-migration with the non-glycosylated form of 7b protein. 
Endo H treatment resulted in a resistant and a sensitive form of 7b protein. The 
major fraction of 7b protein was Endo H-resistant suggesting that this form of 7b 
protein contained complex glycan structures. Since such structures are formed in 
medial- and trans-Golgi (Balch & Keller 1986); 7b protein is retained beyond cis-
Golgi. The Endo H-sensitive fraction of 7b protein apparently represents the not 
completely glycosylated forms of 7b protein that have not yet reached the medial-
Golgi.  
 
3.4 Impact of C-terminal Sequence of 7b Protein on 
Subcellular Localization 
 
3.4.1 Generation of rFIPV-7b(1-206)-flag 
To elucidate whether an additional sequence at the C-terminus of 7b protein alters 
its intracellular localization in FIPV-infected cells, a recombinant FIPV expressing 7b 
protein with a flag tag at its C-terminus (rFIPV-7b(1-206)-flag) was generated using 
vaccinia virus-based reverse genetic system. To generate recombinant vaccinia 
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virus vrFIPV-7b(1-206)-flag, CV-1 cells were infected with vrFIPV-GPT-Δ7ab and 
transfected with pDF4 plasmid, similar as shown in Figure 11. After selection of gpt-
negative recombinant vaccinia virus, viral DNA was isolated and analyzed with PCR 
(Fig. 24). After sequence analysis of the recombination sites, vrFIPV-7b(1-206)-flag 
was plaque purified and the integrity of the viral genome was assessed with PCR as 
described in Figure 10. 
Figure 24. Analysis of recombinant vaccinia virus vrFIPV-7b(1-206)-flag. (A) Positions of the 
PCR fragments, as well as applied primers are presented. Black box represents the flag tag in 7b 
gene. (B) PCR analysis of vrFIPV-7b(1-206)-flag recombinant vaccinia virus DNA. PCR products 
were resolved in ethidium bromide-stained 1% agarose gel. The size of selected marker band is 
shown on the right. I, PCR fragment I; II, PCR fragment II; G, PCR fragment G; M, DNA marker. 
For the recovery of rFIPV-7b(1-206)-flag, the DNA of the recombinant vaccinia virus 
vrFIPV-7b(1-206)-flag was isolated in preparative scale (2.2.3.3.2.2) and analyzed 
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with agarose gel electrophoresis as shown in Figure 13. The DNA was used as a 
template for in vitro transcription (2.2.4.3). In the next step, rFIPV-7b(1-206)-flag 
RNA was electroporated (EP) (2.2.1.6.2) into BHK-FIPV-N cells and co-cultured with 
FCWF-4 cells (2.2.7.2.1). 48 hours post EP, the cell culture supernatant was 
harvested and centrifuged to remove cell debris. Subsequently, the supernatant was 
used to infect fresh FCWF-4 cells. After 24-48 h incubation, the supernatant 
containing rFIPV-7b(1-206)-flag was harvested, stored at -80 °C and used for further 
experiments. The infected cells were used for PCR analyses. After sequencing of the 
PCR-products, insertion of the flag tag at the C-terminus of 7b could be verified (Fig. 
25A). Growth kinetics of rFIPV-7b(1-206)-flag were identical to those of the type II 
FIPV strain 79-1146 (Fig. 25B). 
Figure 25. Characterization of rFIPV-7b(1-206)-flag. (A) Sequence analyses of type II FIPV strain 
79-1146 and rFIPV-7b(1-206)-flag. Flag tag sequence downstream of 7b gene is demonstrated. 3’ 
UTR, 3’ untranslated region. (B) Growth kinetics of rFIPV-7b(1-206)-flag compared to type II FIPV 
strain 79-1146;p.i., post infection. 
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3.4.2 Characterization of 7b Protein Encoded by rFIPV-7b(1-
206)-flag 
CRFK cells were infected with rFIPV-7b(1-206)-flag and cells and cell culture 
supernatant were harvested before CPE developed. The samples were then 
analyzed with Western Blot using anti-Flag® M2 antibody (α-flag mAb) (Fig. 26B). 7b 
protein was detected both in the cell lysate and the cell culture supernatant. The 
higher molecular weight of 7b protein in the supernatant corresponds to further 
glycosylation events that take place during the transport of the protein between the 
Golgi and the cell surface. To determine the localization of C-terminal flag-tagged 7b 
protein in FIPV-infected cells, confocal microscopy analysis was performed (Fig. 
26C). The analysis revealed that the C-terminal flag-tagged 7b protein co-localized 
not only with the Golgi apparatus but it was also detected as dense spots in the 
cytoplasm without association of the Golgi. These data indicate that insertion of a 
flag tag at the C-terminus of 7b protein alters its subcellular localization and leads to 
secretion of 7b protein. Similar observation was made by Dedeurwaerder et. al 
(2014). In this recent study, 7b-GFP fusion protein expressed from a plasmid was 
found to localize with Golgi apparatus and as dense spots in the entire cytoplasm 
outside this compartment. 
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Figure 26. Effect of the C-terminal flag tag on subcellular localization of 7b protein. (A) 
Schematic representation of 7b protein encoded by rFIPV-7b(18-206)-flag. Black box represents the 
position of the flag tag in 7b protein. SP, signal peptide; numbers indicate the amino acid positions in 
7b protein. The arrow represents the signalase cleavage site. (B) CRFK cells were infected with 
rFIPV-7b(1-206)-flag at an MOI of 0.1. Cells and cell culture supernatants were harvested at 16 h p.i.. 
Cell lysate (c) and cell culture supernatant (s) were separated by SDS-PAGE (10 %) under reducing 
conditions and analyzed by Western Blot using anti-flag mAb. (C) CRFK cells were infected with 
rFIPV-7b(1-206)-flag at an MOI of 1. Cells were fixed 16 h p.i. and analyzed by confocal laser 
scanning microscopy. Immunofluorescence staining of 7b protein was performed with anti-flag mAb 
(α-flag mAb). Immunofluorescence staining of the endoplasmic reticulum (ER) (left panel) and the 
Golgi complex (right panel) is shown. Cell nuclei were stained blue with DAPI. The inserts in the lower 
right corner represent an 8x magnification of the selected area (adapted from Florek et al., 2017). 
 
3.4.3 Generation of Recombinant FIPVs with Altered KTEL 
Motif 
To study the influence of the KTEL motif on 7b protein subcellular localization in 
FIPV-infected cells, we generated a set of recombinant FIPVs expressing 7b protein 
with altered KTEL motif. To achieve this, recombinant vaccinia viruses vrFIPV-7b(1-
17/flag/18-202/KTEV), vrFIPV-7b(1-17/flag/18-202/KTE), vrFIPV-7b(1-17/flag/18-
202/AAAA) and vrFIPV-7b(1-17/flag/18-202/KDEL) were generated using vaccinia 
virus-based reverse genetic system. CV-1 cells were infected with vrFIPV-GPT-Δ7ab 
and transfected with plasmids pDF6, pDF7, pDF9 and pDF8, respectively similar as 
shown in Figure 11. After selection of gpt-negative recombinant vaccinia viruses, 
viral DNA was isolated and analyzed with PCR (Fig. 27). After sequence analysis of 
the recombination sites, vrFIPV-7b(1-17/flag/18-202/KTEV), vrFIPV-7b(1-17/flag/18-
202/KTE), vrFIPV-7b(1-17/flag/18-202/AAAA) and vrFIPV-7b(1-17/flag/18-
202/KDEL) were plaque purified and the integrity of the viral genome was assessed 
with PCR as described in Figure 10.  
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Figure 27. Analysis of recombinant vaccinia viruses vrFIPV-7b(1-17/flag/18-202/KTEV), vrFIPV-
7b(1-17/flag/18-202/KTE), vrFIPV-7b(1-17/flag/18-202/AAAA) and vrFIPV-7b(1-17/flag/18-
202/KDEL). (A) Positions of the PCR fragments as well as applied primers are presented. (B) PCR 
analysis of vrFIPV-7b(1-17/flag/18-202/KTEV), vrFIPV-7b(1-17/flag/18-202/KTE), vrFIPV-7b(1-
17/flag/18-202/AAAA) and vrFIPV-7b(1-17/flag/18-202/KDEL) recombinant vaccinia virus DNA. PCR 
products were resolved in ethidium bromide-stained 1% agarose gel. The size of selected marker 
band is shown on the right. I, PCR fragment I; II, PCR fragment II; G, PCR fragment G; M, DNA 
marker. 
For the recovery of recombinant FIPVs, DNA of the obtained recombinant vaccinia 
viruses was isolated in preparative scale (2.2.3.3.2.2) and analyzed with agarose gel 
electrophoresis as shown in Figure 13. The DNA was used as a template for in vitro
transcription (2.2.4.3). In the next step, rFIPV-7b(1-17/flag/18-202/KTEV), rFIPV-
7b(1-17/flag/18-202/KTE), rFIPV-7b(1-17/flag/18-202/AAAA) and rFIPV-7b(1-
17/flag/18-202/KDEL) RNA was electroporated (EP) (2.2.1.6.2) into BHK-FIPV-N
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cells and co-cultured with FCWF-4 cells (2.2.7.2.1). 48 hours post EP, the cell 
culture supernatant was harvested and centrifuged to remove cell debris. 
Subsequently, the supernatant was used to infect fresh FCWF-4 cells. After 24-48 h 
incubation, the supernatant containing rFIPVs was harvested, stored at -80 °C and 
used for further experiments. The infected cells were used for PCR analyses. After 
sequencing of the PCR-products, all respective alterations of KTEL motif could be 
verified (Fig. 28A). Moreover, flag tag downstream of the signalase cleavage site of 
7b was successfully introduced in all rFIPVs (Fig. 28A). Growth kinetics of rFIPV-
7b(1-17/flag/18-202/KTEV), rFIPV-7b(1-17/flag/18-202/KTE), rFIPV-7b(1-17/flag/18-
202/AAAA) and rFIPV-7b(1-17/flag/18-202/KDEL) were identical to those of the type 
II FIPV strain 79-1146 (Fig. 28B). 
According to Vennema and colleagues (1992), KTEL to KTEV alteration abolished 
ER retention and led to secretion of 7b protein. To investigate whether similar results 
can be observed in FIPV-infected cells rFIPV-7b(1-17/flag/18-202/KTEV) was 
generated. A recent study described KXD/E C-terminal motif as a Golgi retention 
signal for various proteins in plants (Gao et al. 2014). In order to elucidate whether 
KTE motif is sufficient for 7b protein retention in the Golgi, leucine at the position 206 
of 7b protein was deleted (rFIPV-7b(1-17/flag/18-202/KTE)). In rFIPV-7b(1-
17/flag/18-202/AAAA) the entire KTEL motif was substituted with 4 alanine residues 
(AAAA). In rFIPV-7b(1-17/flag/18-202/KDEL) KTEL was altered to KDEL motif, which 
represents a canonical ER-retention signal.  
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Figure 28. Characterization of recombinant FIPVs expressing 7b protein with altered C-terminal 
motif. (A) Sequence analyses of rFIPV-7b(1-17/flag/18-206), rFIPV-7b(1-17/flag/18-202/KTEV), 
rFIPV-7b(1-17/flag/18-202/KTE), rFIPV-7b(1-17/flag/18-202/AAAA) and rFIPV-7b(1-17/flag/18-
202/KDEL). Alterations to the C-terminal KTEL motif of 7b protein are shown. In rFIPV-7b(1-
17/flag/18-202/KTEV), the last 3 nucleotides (TTA, leucine) were mutated into GTT (valine). In rFIPV-
7b(1-17/flag/18-202/KTE), the last 3 nucleotides (TTA, leucine) were deleted. In rFIPV-7b(1-
17/flag/18-202/AAAA), the last 12 nucleotides were substituted with GCAGCTGCTGCA (AAAA). In 
rFIPV-7b(1-17/flag/18-202/KDEL), the nucleotides ACT (threonine) were mutated into GAT (aspartic 
acid). Asterisks show positions of respective alterations. 3’ UTR, 3’ untranslated region; ø, 
translational stop codon. (B) Growth kinetics of rFIPV-7b(1-17/flag/18-202/KTEV), rFIPV-7b(1-
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17/flag/18-202/KTE), rFIPV-7b(1-17/flag/18-202/AAAA) and rFIPV-7b(1-17/flag/18-202/KDEL) 
compared to type II FIPV strain 79-1146; p.i., post infection. 
 
3.4.4 Role of the C-terminal KTEL Motif in Subcellular 
Localization of 7b Protein 
CRFK cells were infected with rFIPV-7b(1-17/flag/18-206) and with viruses in which 
the C-terminal KTEL motif in 7b protein was altered (rFIPV-7b(1-17/flag/18-
202/KTEV), rFIPV-7b(1-17/flag/18-202/KTE), rFIPV-7b(1-17/flag/18-202/AAAA) and 
rFIPV-7b(1-17/flag/18-202/KDEL)) (Fig. 29A). Cells and cell culture supernatants 
were harvested before CPE developed. The samples were subjected to SDS-PAGE 
and analyzed with Western Blot using anti-Flag® M2 antibody (α-flag mAb) (Fig. 
29B). 7b protein was detected in all cell lysates. Additionally, 7b protein was 
observed in the cell culture supernatants originating from cells infected with rFIPV-
7b(1-17/flag/18-202/KTEV), rFIPV-7b(1-17/flag/18-202/KTE) and rFIPV-7b(1-
17/flag/18-202/AAAA) suggesting that the C-terminal motifs KTEV, KTE and AAAA in 
7b protein led to secretion of the protein. The higher molecular weight of 7b protein 
in the cell culture supernatant corresponds to further glycosylation events that take 
place after the protein leaves the Golgi and is transported to the cell surface. The 
weak signals in rFIPV-7b(1-17/flag/18-202/AAAA)-infected cells and cell culture 
supernatant may be due to accelerated intracellular degradation of 7b protein. The 
Western blot analyses further revealed that 7b with the KDEL motif was only 
detectable in the cell lysate. 
Immunofluorescence analysis was applied to study the localization of 7b protein in 
cells infected with the different recombinant FIPVs listed above. Cells were fixed and 
7b protein was visualized using anti-Flag® M2 antibody (α-flag mAb) (Fig. 29C). The 
experiments revealed that 7b protein with KTEV, KTE and AAAA motifs co-localized 
with the Golgi apparatus and was also detected as dense spots in the entire 
cytoplasm outside this compartment. 7b protein with C-terminal KDEL motif co-
localized exclusively with the endoplasmic reticulum.  
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Figure 29. Influence of altered C-terminal motifs in 7b protein on subcellular localization and 
secretion. (A) Schematic representation of 7b protein encoded by rFIPV-7b(1-17/flag/18-206), rFIPV-
7b(1-17/flag/18-202/KTEV), rFIPV-7b(1-17/flag/18-202/KTE), rFIPV-7b(1-17/flag/18-202/AAAA) and 
rFIPV-7b(1-17/flag/18-202/KDEL). Black boxes represent the position of a flag tag in 7b. The C-
terminal amino acids of 7b protein are shown; SP, signal peptide; numbers indicate the amino acid 
positions in 7b protein. The arrows represent the signalase cleavage site (B) CRFK cells were 
infected with rFIPV-7b(1-17/flag/18-206), rFIPV-7b(1-17/flag/18-202/KTEV), rFIPV-7b(1-17/flag/18-
202/KTE), rFIPV-7b(1-17/flag/18-202/AAAA) and rFIPV-7b(1-17/flag/18-202/KDEL) at an MOI of 0.1, 
respectively. Cells and cell culture supernatants were harvested at 16 h p.i. Cell lysates (c) and cell 
culture supernatants (s) were separated by SDS-PAGE (10 %) under reducing conditions and 
analyzed by Western Blot using anti-flag mAb (α-flag mAb). (C) CRFK cells were infected with rFIPV-
 
- 95 - 
 
7b(1-17/flag/18-206), rFIPV-7b(1-17/flag/18-202/KTEV), rFIPV-7b(1-17/flag/18-202/KTE), rFIPV-7b(1-
17/flag/18-202/AAAA) and rFIPV-7b(1-17/flag/18-202/KDEL) at an MOI of 1. Cells were fixed 16 h p.i. 
and analyzed by confocal laser scanning microscopy. Immunofluorescence staining of 7b protein was 
performed with anti-flag mAb (α-flag mAb). Immunofluorescence staining of the endoplasmic 
reticulum (ER) (left panel) and the Golgi complex (right panel) is shown. Cell nuclei were stained blue 
with DAPI. The inserts in the lower right corner represent an 8x magnification of the selected area 
(adapted from Florek et al., 2017). 
 
The results can be summarized as follows: substitution of the KTEL motif with KTEV, 
KTE or AAAA altered the subcellular localization of 7b protein and led to secretion of 
it. Replacement of the C-terminal KTEL motif by KDEL resulted in ER-, instead of 
Golgi-retention. Taken together, the performed experiments show that the C-terminal 
KTEL motif of 7b protein is responsible for its localization in the Golgi apparatus in 
FIPV-infected cells. 
 
3.5 Subcellular Localization of 7b Protein after Inhibition of 
Ongoing Protein Synthesis 
Since the so far applied experimental setup cannot differentiate between ongoing 
protein synthesis and 7b synthesized at an earlier time point p.i. in FIPV-infected 
cells, translation was blocked with cycloheximide (CHX) for 2 hours prior fixation. 
After CHX treatment, subcellular localization of 7b protein produced before addition 
of cycloheximide was investigated. For this purpose, CRFK cells were infected with 
rFIPV-7b(1-17/flag/18-202/KTEV), rFIPV-7b(1-17/flag/18-202/KTE), rFIPV-7b(1-
17/flag/18-202/AAAA), rFIPV-7b(1-17/flag/18-206) and rFIPV-7b(1-17/flag/18-
202/KDEL), respectively. 15 h post infection cells were either treated with CHX or left 
untreated. After 2 hour of incubation (17 h post infection), both cycloheximide-treated 
and untreated cells were fixed and analyzed by immunofluorescence (Fig. 30). Anti-
Flag® M2 antibody (α-flag mAb) was used to visualize 7b protein. The subcellular 
localization of 7b protein with altered C-terminal motifs (KTEV, KTE or AAAA) 
differed between cycloheximide-treated and untreated cells. In cells treated with 
cycloheximide, 7b protein did not localize with the Golgi apparatus and only weak 
signals of 7b protein could be detected outside this compartment. In contrast, no 
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change in subcellular localization of 7b protein with KTEL or KDEL motifs was 
observed in cycloheximide-treated versus untreated cells.  
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Figure 30. Effect of cycloheximide treatment on localization of 7b protein with different C-
terminal motifs. CRFK cells were infected with rFIPV-7b(1-17/flag/18-202/KTEV), rFIPV-7b(1-
17/flag/18-202/KTE), rFIPV-7b(1-17/flag/18-202/AAAA), rFIPV-7b(1-17/flag/18-206) and rFIPV-7b(1-
17/flag/18-202/KDEL) at an MOI of 1, respectively. At 15 h p.i., the cells were either treated with 
cycloheximide (+) or left untreated (-). 17 h p.i. cells were fixed and analyzed by confocal laser 
scanning microscopy. Immunofluorescence staining of 7b was performed with anti-flag mAb (α-flag 
mAb). Immunofluorescence staining of the endoplasmic reticulum (ER) (left panel) and the Golgi 
complex (right panel) is shown. Cell nuclei were stained blue with DAPI. CHX, cycloheximide. The 
inserts in the lower right corner represent an 8x magnification of the selected area (adapted from 
Florek et al., 2017).
The localization of 7b protein in FIPV-infected cells after inhibition of the ongoing 
protein synthesis was further analyzed with Endo H treatment followed by Western 
blot analysis (Fig. 31). CRFK cells were infected with rFIPV-7b(1-17/flag/18-206) or 
rFIPV-7b(1-17/flag/18-202/KDEL). 15 hours p.i. the cells were either treated with 
cycloheximide or left untreated. 17 h post infection the cells were harvested and the 
cell lysates were subjected to Endo H treatment or left untreated. The samples were 
then resolved on SDS-PAGE and analyzed with Western Blot using anti-Flag® M2 
antibody (α-flag mAb).These experiments revealed that after cycloheximide 
treatment, 7b protein originating from cells infected with rFIPV-7b(1-17/flag/18-206) 
was completely Endo H-resistant indicating that 7b protein was retained beyond cis-
Golgi compartment. In contrast, 7b protein originating from rFIPV-7b(1-17/flag/18-
202/KDEL)-infected cells was fully sensitive to Endo H digestion regardless of 
cycloheximide treatment suggesting that 7b protein with the C-terminal KDEL motif 
was exclusively retained in the endoplasmic reticulum.  
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Figure 31. Western blot analysis of CHX-treated versus non-treated FIPV-infected cells. (A) 
Schematic representation of 7b protein encoded by rFIPV-7b(1-17/flag/18-206), and rFIPV-7b(1-
17/flag/18-202/KDEL). Black boxes represent the flag tag in 7b protein. The C-terminal four amino 
acids in 7b protein are shown. SP, signal peptide; numbers indicate the amino acid positions in 7b 
protein. The arrows between amino acids 17 and 18 represent the signalase cleavage site. (B) CRFK 
cells infected with rFIPV-7b(1-17/flag/18-206) and rFIPV-7b(1-17/flag/18-202/KDEL) at an MOI of 0.1 
were either treated with cycloheximide (+) or left untreated (-). After 2 h of incubation (17 h p.i.), the 
cells were harvested, lysed and subjected to treatment with Endo H glycosidase (+) or left untreated  
(-). The samples were then resolved in a 10% polyacrylamide gel and analyzed with Western Blot 
using anti-Flag
®
 M2 antibody (α-flag mAb). CHX, cycloheximide. 
 
To verify that the observed results were not specific only to one cell line (CRFK), 7b 
protein localization was studied in other feline cell lines as well. For this purpose, 
FCWF-4 and Fc3Tg cells were infected with rFIPV-7b(1-17/flag/18-206) or rFIPV-
7b(1-17/flag/18-202/KTEV). rFIPV-7b(1-17/flag/18-202/KTEV) was chosen as a 
representative virus, in which alteration of the 7b C-terminal KTEL motif led to 
secretion of the protein. Since in these cell lines cytopathic effect with recombinant 
FIPVs develops faster, cycloheximide treatment was performed 8 h post infection. 
After 2 h of incubation (10 h post infection), both cycloheximide-treated and 
untreated cells were fixed and analyzed with confocal microscopy using anti-Flag® 
M2 antibody (α-flag mAb) (Fig. 32). These experiments showed no differences in 7b 
protein localization in FIPV-infected FCWF-4 or Fc3Tg cells in comparison with 
CRFK cells. Accordingly, in FCWF-4 or Fc3Tg cells 7b protein with an intact C-
terminal KTEL motif was retained in the Golgi. Alteration of the KTEL motif to KTEV 
led to abolishment of Golgi retention and secretion of 7b protein.  
Altogether, the performed experiments revealed that mutation of the C-terminal 
KTEL motif to KTEV, KTE or AAAA abolished Golgi retention and led to secretion of 
7b protein. The results further suggest that independent of ongoing protein 
synthesis, the C-terminal KTEL motif in 7b protein functions as a Golgi retention 
signal. Exchange of only one amino acid (threonine to aspartic acid) resulting in 
KDEL motif turned the Golgi into an ER retention signal. 
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Figure 32. Effect of cycloheximide treatment on localization of 7b protein with different C-
terminal motifs in infected FCWF-4 and Fc3Tg cell lines. FCWF-4 (A) or Fc3Tg (B) cells were 
infected with either rFIPV-7b(1-17/flag/18-206) or rFIPV-7b(1-17/flag/18-202/KTEV) at an MOI of 1, 
respectively. At 8 h post infection the cells were either treated (+) with cycloheximide or left untreated 
(-). 10 h post infection cells were fixed and analyzed by indirect immunofluorescence assay. 7b 
protein was visualized using anti-Flag® M2 (α-flag mAb). Immunofluorescence staining of cell 
structures: endoplasmic reticulum (ER) (left panel) and Golgi apparatus (right panel) is demonstrated. 
Cell nuclei were stained blue using DAPI. Immunofluorescence staining was visualized with confocal 
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laser scanning microscope. CHX, cycloheximide. The inserts in the lower right corner represent an 8x 
magnification of the selected area. 
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4 Discussion 
 
Feline coronaviruses (FCoVs) infect wild and domestic cats worldwide. In most of the 
cases, the infection is asymptomatic with occasional onset of mild enteritis. However, 
in approximately 5% of these cats a lethal disease called feline infectious peritonitis 
(FIP) develops (Chang et al. 2011; Haijema et al. 2007; Heeney et al. 1990; 
Hofmann-Lehmann et al. 1996; Munson et al. 2004; O'Brien et al. 1985; Paul-Murphy 
et al. 1994; Pedersen 2009). Based on antigenic differences, FCoVs are divided into 
two serotypes (I and II) (Heeney et al. 1990; Hohdatsu et al. 1991a; Hohdatsu et al. 
1991b; Kennedy et al. 2003). While serotype I FCoVs are responsible for up to 95% 
of the natural infections, type II FCoVs are less common (Addie et al. 2003; 
Hohdatsu et al. 1992; Kennedy et al. 2002; Kummrow et al. 2005). Serotype II 
FCoVs originate from a double homologous recombination between type I FCoVs 
and type II canine coronaviruses (CCoV) (Decaro & Buonavoglia 2008; Haijema et 
al. 2007; Herrewegh et al. 1998; Lin et al. 2013; Lorusso et al. 2008; Motokawa et al. 
1996; Terada et al. 2014; Vennema 1999). Both serotypes exist in two biotypes. 
FECVs are responsible for asymptomatic persistent infection, while FIPV infection 
leads to FIP. It is widely accepted that FIPVs evolve from FECVs by acquiring 
mutations in persistently infected cats (Chang et al. 2011; Haijema et al. 2007; 
Pedersen 2009; Poland et al. 1996; Vennema et al. 1998). Mutations responsible for 
the biotype switch have not been identified yet, but sequence comparisons between 
FECVs and FIPVs suggested that alterations in the S gene, M gene and accessory 
genes 3c, 7a and 7b may be involved in FIPV development (Bank-Wolf et al. 2014; 
Brown et al. 2009; Chang et al. 2010; Chang et al. 2012; Dedeurwaerder et al. 2013; 
Herrewegh et al. 1995; Kennedy et al. 2001; Licitra et al. 2013; Pedersen et al. 2012; 
Rottier et al. 2005; Takano et al. 2011; Vennema et al. 1998). 
Little is known about the FCoV accessory genes and their products. Using reverse 
genetics, it was shown that these genes are dispensable for virus growth in vitro but 
are important for the virulence in vivo (Haijema et al. 2004). Previous studies 
suggested that ORF 7 is necessary for FIPV replication in monocytes 
(Dedeurwaerder et al. 2013), while an intact ORF 3c is needed for replication in the 
intestine (Balint et al. 2014a; Balint et al. 2014b). Another study suggested that 7a 
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functions as a counteragent of IFN-α induced antiviral responses (Dedeurwaerder et 
al. 2014).  
In contrast to other FCoV-encoded accessory proteins, only the expression of 7b 
protein was experimentally demonstrated in vitro (Lemmermeyer et al. 2016; 
Vennema et al. 1992). Additionally, FCoV 7b antibodies have been detected in sera 
from infected cats indicating the production of 7b protein also in vivo (Herrewegh et 
al. 1995; Kennedy et al. 2008; Vennema et al. 1992). 7b protein has been 
characterized in a heterologous system using recombinant vaccinia virus-infected 
and 7b expression plasmid-transfected HeLa cells (Vennema et al. 1992). The 
authors identified 7b protein as a glycoprotein (26 kDa) with one putative N-
glycosylation site. The N-terminal hydrophobic sequence was suggested to 
represent a signal peptide. 7b protein was proposed to be an ER-resident protein 
containing a KDEL-like ER retention signal (KTEL) at the C-terminus. It is important 
to note, that the subcellular localization of 7b protein was exclusively determined by 
Endoglycosidase H (Endo H) digestion of cell lysates. Additionally, the authors 
showed that 7b protein was secreted and the C-terminal KTEL motif was responsible 
for its slow secretion. The KTEL motif was then characterized and mutated to either 
KTEV or KDEL. The former mutation led to efficient secretion of 7b protein into the 
cell culture supernatant, while the latter resulted in complete retention of 7b protein 
in the ER (Vennema et al. 1992). 
Due to the lack of proper tools, so far, the characterization of FCoV accessory 
proteins in FIPV-infected cells was limited. To overcome this limitation, this study 
focused on the generation of recombinant FCoVs using reverse genetics. The 
recently established vaccinia virus-based reverse genetic system for type II FIPV 
strain 79-1146 (Tekes et al. 2012) was used for this purpose. The generated 
recombinant FIPVs allowed the detailed characterization of 7b protein for the first 
time in FCoV-infected feline cells.  
 
4.1 Localization of 7b Protein in FIPV-infected Cells 
A monoclonal antibody (mAb) against 7b protein has recently been generated to 
study this protein in FCoV-infected cat cells (Lemmermeyer et al. 2016). However, 
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results of the experiments revealed that this mAb did not recognize the mature form 
of 7b protein but only its non-glycosylated precursor. In order to study the localization 
of 7b protein in FIPV-infected cells using this antibody (anti-7b 14D8), a recombinant 
FIPV expressing the non-glycosylated form of 7b protein was generated using 
vaccinia virus-based reverse genetic system. In silico prediction revealed that 7b 
protein possesses only one N-linked glycosylation site at amino acid position 68. 
Since some field viruses contain at this position a serine, in rFIPV-7b(1-206/N68S) 
asparagine was changed to serine (N68S) to remove the glycosylation site in 7b 
protein. rFIPV-7b(1-206/N68S)-infected CRFK cells were then analyzed with 
Western blot and confocal microscopy. Cells were harvested before cytopathic effect 
(CPE) developed to avoid detection of 7b protein in the cell culture supernatant 
caused by cell lysis. The experiments revealed that the non-glycosylated form of 7b 
protein was not secreted but retained in the Golgi apparatus in FIPV-infected cells. 
These results were contradictory to the work of Vennema and colleagues (Vennema 
et al. 1992). 
To clarify whether these discrepancies were related to the absence of glycosylation 
of 7b protein, a different approach was chosen to detect 7b protein. Using vaccinia 
virus-based reverse genetic system, a set of recombinant feline coronaviruses 
expressing flag-tagged 7b protein was generated. Since 7b protein was proposed to 
contain an N-terminal signal sequence, a flag tag was inserted downstream of the 
determined signalase cleavage site. Additionally, a virus expressing flag-tagged, 
non-glycosylated form of 7b protein was generated to enable the comparison of the 
subcellular localization between glycosylated and non-glycosylated forms of 7b 
protein. CRFK cells infected with these two viruses were then analyzed with Western 
blot and confocal microscopy using anti-flag mAb. The results led to the conclusion 
that irrespective of the glycosylation, 7b protein co-localized exclusively with the 
Golgi apparatus and was not secreted. To exclude that the obtained results were 
specific to CRFK cells, the same experiments were performed with other cell lines of 
cat origin. No difference in the subcellular localization of 7b protein could be detected 
in various cat cells (data not shown). 
To determine the compartment of the Golgi, where 7b protein in FIPV-infected cells 
is retained, the cell lysate was subjected to PNGase F or Endoglycosidase H (Endo 
H) treatment. PNGase F treatment resulted in complete removal of the glycan 
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structure. Endo H digestion led to the detection of Endo H-resistant and -sensitive 
forms of 7b protein. However, the majority of 7b protein was Endo H-resistant. Since 
proteins become Endo H-resistant during the glycosylation process in the medial- 
and trans-Golgi (Balch & Keller 1986), the experiments showed that 7b protein was 
retained beyond the cis-Golgi.  The Endo H-sensitive form represents probably the 
prematurely glycosylated forms of 7b protein that have not reached the medial-Golgi 
yet.  
 
4.2 Role of the C-terminal Sequence in the Localization of 7b 
Protein 
In the next experiments, the influence of the C-terminus of 7b protein on its 
subcellular localization was investigated. In order to do so, a virus expressing 7b 
protein flag-tagged at the C-terminus was generated. The experiments showed that 
after infection of CRFK cells, 7b protein was detected both in the cell lysate and the 
cell culture supernatant with Western blot using anti-flag mAb. Confocal microscopy 
analyses revealed that C-terminal flag-tagged 7b protein co-localized not only with 
the Golgi apparatus, but was also observed as dense spots in the entire cytoplasm 
without association of the Golgi to eventually reach the cell surface. Similar results 
were obtained in cells transfected with a plasmid expressing 7b fused with green 
fluorescent protein (GFP) at its C-terminus (Dedeurwaerder et al. 2014). These 
results indicate that the C-terminal flag tag in 7b protein affected the subcellular 
localization and led to secretion of the protein.  
Using the previously described heterologous expression system, the C-terminal 
KTEL motif of 7b protein was suggested to function as a KDEL-like ER retention 
signal (Vennema et al. 1992). However, our results indicated that the C-terminal 
KTEL motif acts as a Golgi, rather than an ER retention signal. To analyze the 
influence of this signal on 7b protein subcellular localization in FIPV-infected feline 
cells, a set of recombinant viruses encoding flag-tagged 7b protein with altered KTEL 
motif was generated using vaccinia virus-based reverse genetic system. (i) Vennema 
and coworkers (1992) showed that leucine to valine exchange in the KTEL motif 
abolished ER retention of the protein and facilitated its secretion. Thus, rFIPV-7b(1-
17/flag/18-202/KTEV) was generated that expresses 7b protein with the C-terminal 
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KETV motif. (ii) A recent study described KXD/E C-terminal motif as a Golgi retention 
signal for various proteins in plants (Gao et al. 2014). In order to elucidate whether 
KTE motif is sufficient for 7b protein retention in the Golgi, rFIPV-7b(1-17/flag/18-
202/KTE) was generated that encodes 7b protein without leucine at aa position 206. 
(iii) In rFIPV-7b(1-17/flag/18-202/AAAA), the entire KTEL motif was substituted with 
4 alanine residues (AAAA). (iv) The C-terminal KDEL motif has been described as a 
canonical ER retention signal for proteins (Capitani & Sallese 2009; Munro & Pelham 
1987; Raykhel et al. 2007). Since Vennema et al. (1992) showed that the exchange 
of the C-terminal KTEL with KDEL motif led to complete retention of 7b protein in the 
ER, rFIPV-7b(1-17/flag/18-202/KDEL) was generated. In this virus, the C-terminal 
KTEL motif in 7b protein was altered into KDEL to investigate whether this change 
will influence 7b protein retention in the Golgi of FIPV-infected cells. CRFK cells 
infected with recombinant FIPVs expressing 7b protein with KTEV, KTE or AAAA 
motif were analyzed with Western blot and confocal microscopy. These alterations of 
the C-terminus led to the detection of 7b protein as dense spots in the entire 
cytoplasm and to secretion. In contrast, the C-terminal KDEL motif conferred 
complete retention of 7b protein in the ER.  
The intracellular localization and trafficking of 7b protein was additionally studied in 
CRFK cells that were treated with cycloheximide (CHX) to block ongoing protein 
synthesis. Only 7b protein with an authentic C-terminal KTEL motif was retained in 
the Golgi apparatus after 2 hours treatment with cycloheximide. In contrast, 7b 
protein with KTEV, KTE or AAAA alterations was barely detectable in infected cells 
and it did not co-localize with the Golgi suggesting that these mutations abolished 
Golgi retention. 7b protein with a KDEL motif was completely retained in the ER.  
To further confirm the localization of 7b protein, infected cells were incubated for 2 h 
with CHX, lysed and subjected to Endo H digestion. 7b protein with an authentic C-
terminal KTEL motif was entirely Endo H-resistant after CHX treatment indicating 
complete retention of the protein beyond the cis-Golgi compartment. Similar 
experiment with 7b protein containing a KDEL motif showed that the protein was 
Endo H-sensitive. This suggests that 7b protein with a KDEL motif did not reach the 
medial-Golgi and was retained in the ER. Altogether, the performed experiments 
indicate that the authentic C-terminal KTEL motif of FIPV 7b protein is crucial for its 
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localization in the Golgi apparatus. Identical results were observed with other feline 
cell lines as well. 
 
4.3 Protein Retention in the ER 
Different mechanisms for protein retention in the endoplasmic reticulum has been 
described. Specific signal motifs in the N-, or C-terminus or in the transmembrane 
domains of proteins were found to confer ER retention (Boulaflous et al. 2009; 
Capitani & Sallese 2009; Gao et al. 2014; Gomord et al. 1999; Nilsson & Warren 
1994; Pelham 1990; Raykhel et al. 2007). Two major ER retention mechanisms that 
require the C-terminal motif of a protein have been described. Both of them are 
based on a COPI-dependent retrograde transport of proteins from the cis-Golgi to 
the ER (Gao et al. 2014). COPI is a protein complex that coats vesicles transporting 
proteins between the Golgi and the ER.  
The first mechanism requires a C-terminal di-lysine motif, where two lysine residues 
are positioned at -3, -4 (KKXX) or -3, -5 (KXKXX) with respect to the C-terminus of a 
protein (Gao et al. 2014; Jackson et al. 1990; Nilsson & von Heijne 1990). This motif 
has been identified in a variety of yeast, plant and mammal proteins (Benghezal et 
al. 2000; Chen et al. 2012; Gaynor et al. 1994; Jackson et al. 1990; Langhans et al. 
2008; Montesinos et al. 2012; Montesinos et al. 2013; Nilsson & von Heijne 1990; 
Townsley & Pelham 1994). The C-terminal di-lysine motif in proteins is recognized 
by subunits of the COPI complex in the cis-Golgi and the protein is transported back 
to the ER (Contreras et al. 2004; Cosson & Letourneur 1994; Langhans et al. 2008; 
Letourneur et al. 1994; Montesinos et al. 2012; Montesinos et al. 2013). However, 
the presence of the KKXX motif at the C-terminus of proteins does not always confer 
ER retention suggesting that other factors might also be important for the retention of 
proteins in the ER (Schroder et al. 1995). 
The second mechanism requires a C-terminal motif different form KKXX. Based on 
current knowledge, proteins with KDEL or similar C-terminal motifs (e.g. KTEL, 
HDEL) are recognized by KDEL receptors located in the cis-Golgi compartment and 
retrieved to the ER by a COPI-dependent retrograde transport (Capitani & Sallese 
2009; Gupta et al. 2012; Raykhel et al. 2007; Vennema et al. 1992) (Fig. 33). ER 
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retention of various proteins has been associated with the presence of a KDEL/KTEL 
motif at their C-terminus (Byun et al. 2007; Gupta et al. 2012; McCoy et al. 2012).
Binding of the target protein to the KDEL receptor is pH dependent. Lower pH of the 
Golgi apparatus results in association, while higher pH in the lumen of the ER leads 
to the dissociation of the receptor-protein complex (Wilson et al. 1993).
Figure 33. Retention of proteins with C-terminal KDEL/KTEL motifs in the ER. Following 
translation, a protein with C-terminal KDEL/KTEL motifs (red) is transported to the Golgi apparatus. 
KDEL receptors (black) recognize KDEL/KTEL motifs and induce retrograde transport of the protein to 
the endoplasmic reticulum (ER).  
Up to date, three isoforms of KDEL receptors have been identified with a sequence 
identity between 80% and 90% (Capitani & Sallese 2009). These isoforms recognize 
and bind proteins with a variety of C-terminal motifs with variable efficiency, 
suggesting that certain proteins bind preferentially to one specific isoform (Capitani & 
Sallese 2009; Raykhel et al. 2007). The efficiency of binding of proteins containing 
different C-terminal motifs by KDEL receptors was compared in human (HeLa) cells 
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(Raykhel et al. 2007). The analyses revealed that the KTEL motif was recognized by 
KDEL receptors with almost the same efficiency as the KDEL motif. KDEL receptors 
homologs are present in other mammalian species as well. The amino acid 
sequence comparisons between the corresponding cat and human KDEL receptors 
revealed 99%, 98.6% and 95% amino acid identity, respectively. The ligand binding 
specificity of the cat KDEL receptors in comparison with human isoforms is not 
known.  
We assume that, in the study of Vennema et al. (1992), 7b protein was efficiently 
recognized by KDEL receptors in HeLa cells and thereby retained in the ER. By 
contrast, the results of the experiments performed in this work suggest that KDEL 
receptors in cat cell lines do not recognize the KTEL motif at the C-terminus of 7b 
protein. Accordingly, 7b protein is transported to the Golgi. It is important to note, 
that the lack of 7b protein binding by the KDEL receptors does not explain its 
retention in the Golgi apparatus. It appears likely that FIPV 7b protein interacts with a 
so far unidentified viral or cellular protein that confers Golgi retention in FIPV-
infected cells (Fig. 34). Similar mechanisms were described for numerous proteins, 
for which Golgi retention was accomplished by protein-protein interactions (Banfield 
2011; Fukasawa et al. 2004; Gao et al. 2014; Kamena et al. 2008; Munro 1998; 
Setty et al. 2004).  
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Figure 34. Model for FCoV 7b Golgi retention in FCoV-infected feline cells. Following translation, 
7b protein with C-terminal KTEL motif (red) is transported to the Golgi apparatus. Feline KDEL 
receptors (black) are unable to recognize KTEL motif in 7b protein and fail to induce retrograde 
transport of the protein to the endoplasmic reticulum (ER). Accordingly, 7b protein is transported to 
the medial/trans-Golgi where it interacts with a so far unidentified protein (blue) that confers Golgi 
retention. 
The experiments performed in this work further suggest that alterations of the C-
terminal KTEL motif of 7b protein either by mutation (KTEV, KTE and AAAA motifs) 
or by insertion of a flag tag abolish this interaction that consequently leads to 
secretion of 7b protein (Fig. 35).  
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Figure 35. Model for FCoV 7b trafficking with C-terminal KTEV motif in FCoV-infected feline 
cells. Following translation, 7b protein with C-terminal KTEV motif (red) is transported to the Golgi 
apparatus. Feline KDEL receptors (black) are unable to recognize KTEV motif in 7b protein and fail to 
induce retrograde transport of the protein to the endoplasmic reticulum (ER). 7b protein with the 
altered C-terminal motif cannot bind toits hypothetical interaction partner (blue) and Golgi retention is 
abolished. Accordingly, 7b protein follows the secretory pathway through the medial/trans-Golgi to the 
cell membrane, where it is released. 
KDEL receptor-mediated retrograde protein transport may also provide a reasonable 
explanation for the different observations in 7b protein secretion in the present work 
and a previous study (Vennema et al. 1992). It has been reported that 
overproduction of an ER resident protein can lead to secretion by saturation of the 
KDEL receptor-triggered retention system (Gupta et al. 2012; Munro & Pelham 1987; 
Semenza et al. 1990). Such a mechanism could serve as an explanation why in 
HeLa cells the vaccinia virus-based robust expression system used by Vennema and 
colleagues (1992) led to secretion of 7b protein despite efficient ER retention. 
Vennema and coworkers (1992) also reported 7b protein secretion in infected cat 
cells. However, they did not provide any data at which time p.i. 7b protein was 
detected in the cell culture supernatant. It is likely, that 7b protein was released into 
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the supernatant due to cell damage caused by FCoV infection at late time points p.i.. 
This is consistent with our own data, since 7b protein was also found in the 
supernatant of FCoV-infected cat cells after development of CPE (data not shown). 
What is the function of 7b protein and why intercellular retention of this protein is 
beneficial for the virus remain to be elucidated. We speculate that retention of 7b 
protein in the Golgi apparatus may contribute to avoid immune recognition and 
consequently be important for establishment of persistent infection. Further studies 
are required to test this hypothesis. 
Taken together, the data of the current study provides important information on 7b 
protein and new insight into a Golgi retention signal that controls the trafficking of this 
protein in FIPV-infected cells. 
  
 
- 112 - 
 
5 Summary 
 
Feline infectious peritonitis (FIP) is one of the most important lethal infectious 
diseases of cats. The genome of Feline infectious peritonitis virus (FIPV) contains 
five accessory genes: 3a, 3b, 3c, 7a and 7b. Due to the lack of proper immunological 
tools, so far, the characterization of putative FIPV accessory proteins was limited. In 
this study, expression, processing, glycosylation, subcellular localization and 
trafficking of the accessory protein 7b was studied for the first time in FIPV-infected 
cells. The following results were obtained: 
 
1.  Recombinant FIPV (rFIPV) expressing non-glycosylated form of 7b protein 
was generated using vaccinia virus-based reverse genetic system. 
Expression and subcellular localization of this protein in FIPV-infected cells 
was analyzed with Western blot and confocal microscopy using anti-7b 
monoclonal antibody (mAb). The data showed that the non-glycosylated form 
of 7b protein is not secreted but co-localizes with the Golgi apparatus.  
 
2. To characterize the mature, glycosylated form of 7b protein, rFIPVs 
expressing flag-tagged 7b proteins were generated by reverse genetics. The 
flag tag was positioned downstream of the signalase cleavage site that was 
determined with N-terminal Edman sequencing. Expression and subcellular 
localization of the flag-tagged, mature form of 7b protein in FIPV-infected cells 
was investigated using Western blot and confocal microscopy with anti-flag 
mAb. Furthermore, the state of glycosylation of 7b protein was determined 
with Western blot after treatment with glycosidases. The obtained results 
indicated that the mature form of 7b protein is not secreted but retained in the 
medial/trans Golgi. 
 
3. The C-terminal KTEL motif in 7b protein was altered to investigate its 
influence on the protein subcellular localization in FIPV-infected cells. 
 
- 113 - 
 
Recombinant FIPVs expressing flag-tagged 7b protein with modifications in 
the C-terminal KTEL motif were generated using reverse genetics. Expression 
and subcellular localization of the 7b protein with altered C-terminal KTEL 
motifs in FIPV-infected cells was investigated with Western blot and confocal 
microscopy using anti-flag mAb. Additionally, the subcellular localization and 
trafficking of the 7b protein with altered C-terminal motifs was analyzed after 
inhibition of ongoing protein synthesis. It was shown that 7b protein only with 
an intact C-terminal KTEL motif was retained in the Golgi apparatus. KTEL to 
KDEL exchange led to ER retention of the protein, while KTEV, KTE and 
AAAA alterations abolished Golgi retention and led to efficient secretion of 7b 
protein. 
 
The results of the current work provide important information on 7b protein and new 
insight into a Golgi retention signal that controls the trafficking of this protein in FIPV-
infected cells. Further studies are required to elucidate the exact role of 7b in the 
coronaviral life cycle.  
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6 Zusammenfassung 
 
Feline infektiöse Peritonitis (FIP) gehört zu den wichtigsten meist tödlich 
verlaufenden infektiösen Erkrankungen der Katze. Das FIPV Genom enthält fünf 
akzessorische Gene: 3a, 3b, 3c, 7a und 7b. Da keine geeigneten immunologischen 
Reagenzien gegen die akzessorischen Proteine zur Verfügung stehen, war die 
bisherige Charakterisierung dieser Proteine limitiert. In Rahmen dieser Arbeit wurden 
die Expression, Prozessierung, Glycosylierung, subzelluläre Lokalisierung und 
Transport des akzessorischen Proteins 7b zum ersten Mal in FIPV-infizierten Zellen 
untersucht. Folgende Ergebnisse wurden erhalten: 
 
1. Rekombinantes FIPV (rFIPV), welches eine nicht-glykosylierte Form des 7b 
Proteins exprimiert, wurde unter Nutzung eines Vaccinia Virus-basierten 
revers-genetischen Systems erzeugt. Die Expression und die subzelluläre 
Lokalisierung dieses Proteins wurden sowohl mit Western Blot als auch mit 
konfokaler Mikroskopie unter Verwendung von anti-7b monoklonalem 
Antikörper (mAk) in FIPV-infizierten Zellen analysiert. Die erhaltenen Daten 
zeigten, dass die nicht-glykosylierte Form von 7b Protein nicht sezerniert wird 
und mit dem Golgi-Apparat kolokalisiert. 
 
2. Zur Charakterisierung der glykosylierten Form des 7b Proteins wurden 
rFIPVs, die das 7b Protein mit Flag-Tag exprimieren, mit Hilfe eines revers-
genetischen Systems erzeugt. Der Flag-Tag wurde stromabwärts der 
Signalase-Spaltstelle positioniert, welche mittels N-terminaler Edman-
Sequenzierung bestimmt wurde. Die Expression und die subzelluläre 
Lokalisierung der Flag-Tag-markierten, glykosylierten Form des 7b Proteins 
wurden unter Verwendung von Western Blot und konfokaler Mikroskopie mit 
anti-Flag mAk in FIPV-infizierten Zellen untersucht. Weiterhin wurde der 
Glycosylierungszustanddes 7b Proteins nach Behandlung mit Glycosidasen 
mittels Western Blot ermittelt. Die erhaltenen Ergebnisse zeigten, dass die 
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glykosylierte Form von 7b nicht sezerniert, sondern in dem medial/trans Golgi-
Apparat zurückgehalten wird. 
 
 
3. Um den Einfluss des C-terminalen KTEL-Motivs auf die subzelluläre 
Lokalisation von 7b in FIPV-infizierten Zellen zu untersuchen, wurde diese 
Sequenz verändert. Rekombinante FIPVs, die ein Flag-Tag-markiertes 7b 
Protein mit Modifikationen im C-terminalen KTEL-Motiv exprimieren, wurden 
unter Nutzung reverser Genetik erzeugt. Die Expression und die subzelluläre 
Lokalisation des 7b Proteins mit veränderten C-terminalen KTEL-Motiven 
wurden mit Western Blot und konfokaler Mikroskopie unter Verwendung von 
anti-Flag mAk in FIPV-infizierten Zellen untersucht. Weiterhin wurden die 
subzelluläre Lokalisierung und der Transport von 7b Protein mit veränderten 
C-terminalen Motiven nach Inhibierung der fortlaufenden Proteinsynthese 
analysiert. Es konnte gezeigt werden, dass 7b Protein nur mit einem intakten 
C-terminalen KTEL-Motiv im Golgi-Apparat zurückgehalten wird. KTEL-zu-
KDEL-Austausch führte zur ER-Retention des Proteins, während KTEV-, 
KTE- und AAAA-Veränderungen die Golgi-Retention aufhoben und zu einer 
effizienten Sekretion des 7b Proteins führten. 
 
Die präsentierten Ergebnisse der vorliegenden Arbeit liefern wichtige Informationen 
über 7b und ein neues Golgi-Retentionssignal, welches den subzellulären Transport 
von diesem Protein in FIPV-infizierten Zellen bestimmt. Weitere Versuche sind nötig, 
um die genaue Funktion von 7b in dem coronaviralen Lebenszyklus zu erforschen. 
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Functional characterization of accessory 
protein 7b encoded by feline coronaviruses
INAUGURAL DISSERTATION 
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